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ABSTRACT 
The anti-inflammatory properties of four medicinal plants were investigated. 
These plant extracts were subjected to screening for their possible effects as 
antioxidative, analgesic, and anti-inflammatory agents. In the antioxidant activity, the 
Plantago lancelota extracts resulted in an IC50 value of 0.4 mg/mL compared to the 
positive control quecertin with IC50 0.04 mg/mL Plantago lanceolata inhibited COX-2 
activity with IC50 values of 0.41 mg/mL. However, the COX-1 inhibition indicated an 
IC50 of 68.99 mg/mL. The lipoxygenase assay indicated that Plantago lanceolata was 
the most active plant species with an IC50 value of 4.86 mg/mL compared to the 
positive control (quecertin) with an IC50<2mg/mL. The nitric oxide assay of the plant 
extracts indicates a dose-dependent activity of our plant extracts. Likewise the cell 
viability result indicated a good activity at dose 100 mg/mL.  
 
Key words: Plantago lanceolata, Conyza canadensis, Acokantera oppositifolia, 
Artemisia vulgaris, antioxidant, anti-inflammatory, nitric oxide, cell viability, Raw 
264.7 macrophages, lypoxygenase, cyclooxygenase-1 and cyclooxygenase-2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 
TABLE OF CONTENTS 
Declaration…………………………………...……………………………………………… 
vi 
 
Dedication…………………………………………………………………………………... vi 
 
Acknowledgement…….………………………………………..………………………… vi 
 
Abstract….……………………….……………………..…………………………………… 
vi 
 
Table of contents…….………………………….……………...………………………….. vi 
 
List of non-standard abbreviations………………………………………………………....vi 
  
List of tables……………………………………………………………………………….… vi 
  
List of figures………………………………………………………………………………….vi 
  
CHAPTER ONE ......................................................................................................... 2 
1. Introduction ............................................................................................................ 2 
1.1 Overview of pain ............................................................................................... 2 
1.2 Inflammation ..................................................................................................... 3 
1.2.1 Acute inflammation ..................................................................................... 4 
1.2.2 Chronic inflammation .................................................................................. 5 
1.3 Aim of the study ................................................................................................ 6 
1.4 Objectives ......................................................................................................... 6 
 
 
vii 
 
Chapter 2 Literature review ........................................................................................ 7 
2.1 Introduction ....................................................................................................... 7 
2.2 Traditional medicine .......................................................................................... 7 
2.2.1Herbal medicines ......................................................................................... 7 
2.2.2 Medicinal plants of South Africa .................................................................. 9 
2.2.3 Traditional healing in South Africa ............................................................ 10 
2.2.4 Other aspects of traditional medicine in South Africa ............................... 10 
2.3 Some medicinal plants used against pain and inflammation ........................... 10 
2.3.1 Boophone disticha .................................................................................... 11 
2.3.2 Lippia javanica .......................................................................................... 11 
2.3.3 Anemone vesicatoria ................................................................................ 12 
2.3.3.1 Plant descrioption……………………………………………………………12 
2.3.3.2 Medicinal uses of Ademone vesicatoria……………………………….…..…...13 
2.3.3.3 Active ingredients……………………………………………...………..……..….13 
2.4 Plants used in this study ................................................................................. 14 
2.4.1 Plantago lanceolata .................................................................................. 14 
2.4.2 Acokanthera oppositifolia .......................................................................... 16 
       2.4.2.1 Botanical description……………………………………...…………………….16 
      2.4.2.2 Medicinal uses………………………………….………..……………..…….17 
      2.4.2.3 Preparation and dosage………………………………..…………………....17 
      2.4.2.4 Active ingredients……………………………..………………………………17 
      2.4.2.5 Pharmacological effects……………………………...………………………18 
      2.4.2.6 Distribution…………………………….…………………………..…………..18 
2.4.3 Artemisia vulgaris ..................................................................................... 18 
2.4.4 Conyza Canadensis .................................................................................. 20 
 
 
viii 
 
2.5 Phytochemical analysis of plants .................................................................... 21 
2.6 Antioxidative activity ........................................................................................ 22 
   2.7 Pathways of inflammation………………………………………….……………….23 
2.7.1 Cyclooxygenase pathway ......................................................................... 23 
       2.7.1.1 Mechanism of action…………………………………..…………………….26 
2.7.2 The lipoxygenase pathway ....................................................................... 27 
2.7.3 Nitric oxide ................................................................................................ 29 
       2.7.3.1 Nitric oxide chemestry…………………….………………….……………..29 
      2.7.3.2 Nitric oxide and inflammation………………………………………………..30 
2.8 mechanism of pain .......................................................................................... 30 
2.8.1 Inflammation related pain.......................................................................... 30 
2.8.2 Nociceptive Afferent Neurons ................................................................... 31 
2.8.3 Modulation in the nociceptive pathway ..................................................... 31 
2.8.4 Transmission of Pain to Higher Centres ................................................... 31 
2.8.5 Neuropathic Pain ...................................................................................... 32 
2.9 Types of analgesics ........................................................................................ 32 
2.9.1 Opioids analgesics .................................................................................... 33 
2.9.2 Morphine analogues ................................................................................. 34 
2.9.3 Non-steroidal anti-inflammatory drugs (NSAIDS) ..................................... 34 
       2.9.3.1 Aspirin……………………………...……………………………..…………..35 
       2.9.3.2 Paracetamol…………………………...……………………………………..35 
CHAPTER 3 MATERIALS AND METHODS ............................................................ 36 
3.1 Introduction ..................................................................................................... 36 
3.2 Plant collection ................................................................................................ 36 
3.3 Plant extraction ............................................................................................... 36 
    3.4 Extraction of plant material for phytochemical analysis………………………...37 
 
 
ix 
 
3.4.1 Test for anthraquinones ............................................................................ 37 
3.4.2 Test for terpenoids .................................................................................... 37 
3.4.3 Test for flavonoids .................................................................................... 38 
       3.4.4 test for saponins………………………………………………………………..38 
3.4.5 Test for tannins ......................................................................................... 38 
3.4.6 Test for cardiac glycosides ....................................................................... 38 
3.4.7 Test for steroids ........................................................................................ 39 
3.4.8 Test for quinones ...................................................................................... 39 
3.4.9 Test for coumarin ...................................................................................... 39 
     3.5 1, 1-diphenyl-2-picryl-hydrazyl assay ......................................................... 39 
3.5.1 Plate layout for DPPH  assay .................................................................... 39 
3.6 Cyclooxygenase-1 and cyclooxygenase-2 assay ............................................ 40 
3.6.1 Material used ............................................................................................ 41 
       3.6.2 Description of Acetylcholinesterase Tracer (ACETM) competitive Enzyme 
Immunoassays (EIAS)……………………………………………………………………..41 
3.6.3 Performing cyclooxygenase reactions ...................................................... 41 
3.6.4 Preparation of assay-specific reagents ..................................................... 42 
       3.6.4.1 Prostaglandin screening standard……………………...………………….42 
       3.6.4.2 Cyclooxygenase reaction dilutions………………………………..……….42 
3.6.5 Ninety-six well plate set up for cyclooxygenase reaction dilutions. ........... 42 
3.6.6 Performing of enzyme immunoassay ........................................................ 43 
3.6.7 Development and reading of the plate ...................................................... 43 
3.6.8 Preparation and data calculation .............................................................. 44 
3.7 Lipoxygenase assay ....................................................................................... 45 
3.7.1 Kit material supplied ................................................................................. 45 
3.7.2 Material needed but not supplied by cyclooxygenase-1 and 
cyclooxygenase-2 kit material ............................................................................ 45 
 
 
x 
 
3.7.3 Reagent preparation ................................................................................. 45 
3.7.4 Arachidonic Acid (Substrate) .................................................................... 46 
        3.7.5 Plate setup………………………………………..……………………………46 
3.7.6 Assay procedure ....................................................................................... 47 
3.7.7 Data analysis ............................................................................................ 48 
3.8 Nitric oxide assay ............................................................................................ 48 
3.8.1 Material used for Nitric Oxide assay ......................................................... 48 
3.8.2 Preparation of growing cells ...................................................................... 49 
3.8.3 Sub culturing cells ..................................................................................... 49 
3.8.4 Cells counting ........................................................................................... 50 
       3.8.5 Nitric oxide performing………………………………………...………………50 
       3.8.5.1 Nitric oxide inhibitory assay in lipopolysaccharide-activated mouse 
leukaemic monocyte macrophage cell line (RAW 264.7 Macrophages)…………….50 
3.9 Cell viability (toxicity) .......................................................................................... 51 
3.9.1 Cytotoxicity activity by 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-4H 
tetrazolium bromide assay ................................................................................. 52 
CHAPTER 4 RESULTS AND DISCUSSION………….....……………………….…….53 
4.1 Introduction ..................................................................................................... 53 
4.2 Phytochemical analysis ................................................................................... 53 
4.3 Antioxidative test ............................................................................................. 54 
4.4 Anti-inflammatory activity ................................................................................ 56 
4.4.1 Cyclooxygenase-1 and cyclooxygenase-2 test ......................................... 56 
       4.4.2 Lipoxygenase assay……………………….…………..………………………60 
    4.5 Nitric oxide test……………………….………………..……………………………62 
4.6 Cytotoxicity test ............................................................................................... 66 
CHAPTER 5 DISCUSSION AND CONCLUSION .................................................... 67 
 
 
xi 
 
REFERENCES ......................................................................................................... 71 
Appendix: RAW DATA ............................................................................................. 82 
A- Antioxidant analysis .......................................................................................... 82 
 
LIST OF NON-STANDARD ABBREVIATIONS 
 
AA                       Arachidonic acid 
ACETM         Acetylcholinesterase tracer 
Ache    Acethycholinesterase  
BK     Bradykinin 
BLK     Blank 
bNOS     Brain nitric oxide synthase 
Bo     Maximum binding 
CGRP    Calcitonin gene-related peptide 
CHF                   Congestive heart failure 
CML    Chronic myeloid leukaemia 
COX-1               Cyclooxygenase-1 
COX-2               Cyclooxygenase-2 
DMEM               Dulbecco’s modified eagle medium 
DMSO    Dimethyl sulfoxide  
DPPH                2, 2’-diphenyl-1-picrylhydrazyl 
EDTA    Ethylenediaminetetra-acetic acid 
EIA    Enzyme immunoassay 
 
 
xii 
 
EL    Endothelium 
eNOS    Endothelium nitric oxide synthase  
FCS    Foetal calf serum 
HPLC    High performance liquid chromatography 
5-HETE    5-hydroxy eicosatetraenoic acid 
5-HPETE           5-hydroperoxy eicosatetraenoic acid 
5-HT    5-hydroxytryptamine 
IBD    Inflammation bowel disease 
IC50    Inhibition concentration with 50% inhibition 
IL    Interleukin  
iNOS    Inducible nitric oxide synthase 
KOH    Potassium hydroxide 
LOX    Lipoxygenase 
LPS                   Lipopolysaccharide 
LT     Leukotriene 
MS   Multiple sclerosis 
MTT   3(4,5-imethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide 
NGF   Nerve growth factor 
NO   Nitric oxide 
NOS   Nitric oxide synthase 
NSAIDs   Non-steroidal anti-inflammatory drugs 
NSB   Non-specific binding 
PAF   Platelet-activating factor 
 
 
xiii 
 
PBS                  Phosphate buffer saline 
PGI2   Prostacyclin 
PLA2   Phospholipase A2 
POMC   Pro-opomelanocortin 
PSF   Penicillin streptomycin fungizone 
PUFA   Polyunsatured fatty acid 
RNOS   Reactive nitrogen oxide species 
ROS   Reactive oxygen species   
SP   Substance P 
SRS-A   Slow-reaction substance  
TA   Total activity 
TLRs   Toll-like receptors 
TNF-α   Tumour necrosis factor alpha 
TX   Thromboxane 
 
 
  
 
 
xiv 
 
LIST OF TABLES 
 
Table 4.1:  Premiminary phytochemical analysis of plant extracts............................54 
Table 4.2: Antioxidative test results .......................................................................... 55 
Table 4.3 Anti-cyclooxygenase-1 results of plant extracts ........................................ 58 
Table 4.4: Anti-cyclooxygenase-2 results of plant extracts ....................................... 59 
Table 4.5: Inhibition of NO by plant extracts ............................................................. 62 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
xv 
 
LIST OF FIGURES 
 
Figure 2.1: Plantago lanceolata L with flowering stalks and numerous inconspicious
 ................................................................................................................................. 15 
Figure 2.2: Acokanthera oppositifolia Lam. .............................................................. 17 
Figure 2.3: Artemisia vulgaris. the leaves can be up to 15 cm long………………….19 
Figure 2.4: Conyza canadensis ................................................................................ 21 
Figure 2.5: Cyclooxygenase-1 and cyclooxygenase-2 ............................................. 25 
Figure 2.6: Arachidonic acid metabolism .................................................................. 29 
Figure 3.1: Ninety-six plates ready for reading ......................................................... 47 
Figure 4.1: Antioxidative activity ............................................................................... 56 
Figure 4.2: Cyclooxygenase-1 inhibition of plant extracts ........................................ 58 
Figure 4.3: Cyclooxygenase-2 inhibition of plant extracts ........................................ 59 
Figure 4.4: Anti-lipoxygenase activity in test1, test2, and test3 ................................ 61 
 
 
 
 
 
 
 
 
 
1 
 
2 
 
CHAPTER ONE 
1. Introduction  
1.1 Overview of pain  
Pain is a common health problem with substantial socioeconomic impact 
because of its high incidence. It is a symptom of many diseases. It is estimated that 
80-100% of the world’s population experience back pain at least once in their life 
time (Jain et al., 2002). The treatment of pain requires analgesics, including anti-
inflammatory products. Most of the so-called non-steroidal anti-inflammatory agents 
also have analgesic activity. Although many analgesics and anti-inflammatory agents 
are present in the market, modern drug therapy is associated with some adverse 
effects, like gastrointestinal irritation, fluid retention, bronchospasm and prolonged 
bleeding time (Osadebe and Okoye, 2003; Jain et al., 2002). 
 
The World Health Organisation (WHO) estimates that up to 80% of the people 
in developing countries still depend on local medicinal plants to fulfil their primary 
healthcare needs (WHO 2002). In certain African countries, up to 90% of the 
population still relies exclusively on plants as sources of medicines (Hostettman et 
al., 2000). Furthermore, an estimated 25% of prescription drugs and 11% of drugs 
considered essential by WHO are derived from plants. A large number of synthetic 
drugs are obtained from precursor compounds originating from plants (Hostettman et 
al., 2000). According to Konno (2004), easy accessibility, efficacy and affordability 
drive the massive preference traditional medicine over modern medication in 
developing and third world countire. In Sub-Saharan Africa, the ratio of traditional 
healers to the population is approximately 1:500, while medical doctors have a 
1:40000 ratios to the rest of the population (Konno, 2004). 
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1.2 Inflammation 
Inflammation is the response of the organism to invasion by a foreign body, 
such as bacteria, parasite, or viruses. In this context, the inflammatory response is a 
critical protective reaction to irritation, injury, or infection, characterized by redness, 
heat swelling, loss of function, and pain (Levine and Reichling, 1999). Redness and 
pain result from an increase in blood flow, swelling is associated with increased 
vascular permeability, and pain is a consequence of activation and sensitisation of 
primary afferent nerve fibres. Under normal conditions, these changes in inflamed 
tissue serve to isolate the effects of the tissue damage or infection and thereby limit 
the threat to the affected site (Levine and Reichling, 1999). 
 
 Inflammation is a process involving localised increases in the number of 
leukocytes and a variety of complex mediator molecules. Prostaglandins are 
ubiquitous substances that modulate cellular and tissue responses involved in 
inflammation (Lipsky, 1999). Their biosynthesis has also been implicated in the 
pathophysiology of cardiovascular diseases, cancer, colonic adenomas and 
Alzheimer’s disease (Smith, 1995; Lipsky, 1999). Inflammation is designed to limit 
invasions and damage after injury, an essential process for the survival of mankind 
in the absence of medication such as antibiotics. The onset to conclusion of an 
inflammation is a self-limiting and controlled process of the immune system 
(Margarethe et al., 2012).   
 
General understanding of the molecular and cellular mechanisms involved in 
the inflammatory process has increased dramatically in recent decades, and has 
permitted the discovery of many promising targets for the development of new drugs 
to treat chronic diseases such as rheumatoid arthritis, allergy, asthma, inflammatory 
bowel disease and others. A great number of inflammatory mediators including 
kinins, platelet-activating factors, prostaglandins, leukotrienes, amines purines, 
cytokines, chemokine, and adhesion molecules act on specific targets, leading to the 
local release of other mediators from leukocytes (e.g. mast cells and basophiles) and 
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the further attraction of leukocytes, such as neutrophils, to the site of inflammation 
(Levine and Reichling, 1999). 
 
To appreciate the inflammatory process, it is important to understand the role 
of chemical mediators. These mediators are the substances released as plasma 
proteins, or secreted by cells like mast cells, platelets, neutrophils and 
monocytes/macrophages following stimulation by allergic or chemical irritation, injury 
and infections (Shailasre et al., 2012). These mediators, depending on the duration 
of injury, or trigger determine the severity of inflammation and are termed pro-
inflammatory fundamental factors. These substances bind to specific target 
receptors on the cells and may increase vascular permeability, promote neutrophil 
chemotaxis, stimulate smooth muscle contraction, increase direct enzymatic activity, 
induce pain and/or mediate oxidative damage (Coleman, 2002). Examples of these 
mediators include: nitric oxide (NO), prostaglandins (PG), leukotriene (LK), 
vasoactive amines (histamine, serotonin), and cytokines (tumour necrosis factor and 
interleukins–1, 12). Although some of the cytokines (IL-3 -4,-5,-6,-10,-13) released 
are beneficial by acting as anti-inflammatory mediator within the cells (Esch and 
Stefano, 2002), these are pro-inflammatory. Even though the innate cascade 
process of inflammation is complex, it is mainly divided into two parts i.e. acute and 
chronic which could either be beneficial or detrimental.  Under specific circumstance, 
it could turn into a chronic state and subsequently become a causative factor in the 
pathogenesis. Inflammation is a self-defence reaction in its first phase, hence 
regarded as the main therapeutic target and often, the best choice to treat the 
disease and alleviate the associated symptoms (Shailasre et al., 2012). 
 
1.2.1 Acute inflammation  
Acute inflammation is short-term response characterised by rapid onset. It is 
characterised by the exudation of fluids and plasma proteins; and the migration of 
leukocytes, most notably neutrophils into the injured area. This acute inflammatory 
response is believed to be a defence mechanism aimed at the killing of bacteria, 
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viruses and parasites with simultaneous facilitations of wound repairs (O’Byrne and 
Dalgleish, 2001; Dalgleish and O’Byrne, 2002). 
 
The inflammatory response stimulates release of Tumour Necrosis Factor 
alpha (TNF-α) from stimulated mast cells. Other cells involved in inflammation have 
receptors for TNF-α. They are activated by the binding of TNF-α. Activation of these 
recruited cells produces their own mediators of inflammation. This positive feedback 
quickly amplifies the response. The phagocytotic cells, macrophages and 
neutrophils, produce reactive oxygen species (ROS). Macrophages and activated 
platelets release interleukin (IL)-1, a cytokine. IL-1 causes fever by stimulating the 
release of prostaglandins (PGs), which act on the temperature control centre of the 
hypothalamus (Duff and Durum, 1982). IL-1 is synthesised from a larger precursor 
that is cleaved by caspase-1. Caspase-1 is part of two (or more) multi- protein 
complexes in the cytosol of macrophages and neutrophils that are called 
inflammasomes (Franchi et al., 2009). Inflammasomes are activated by several 
different products produced by invading bacteria that interact with toll-like receptors 
(TLRs), thus providing a link between the innate immune system and inflammation. 
Chemical mediators such as histamine and bradykinin induce the production of PGs 
and leukotrienes with a role to potentiate the plasma exudation (Oh-Ishi, 1997). 
These potent mediators of inflammation are derivatives of arachidonic acid (AA), a 
20-carbon unsaturated fatty acid produced from membrane phospholipids. 
        
Arachidonic acid, esterified at the second carbon in the glycerol backbone of 
membrane phospholipids is released in a hydrolytic reaction catalysed by 
phospholipase A2 (PLA2). It is subsequently metabolized by cyclooxygenase (COX) 
and lipoxygenase (LOX) to prostaglandins. The COX-1 is constitutively expressed 
and produces PGs in a basic housekeeping manner for normal functioning of the 
body. The expression of COX-2 is inducible, upregulated in response to cytokines, 
mitogens and endotoxins (Shailasre et al., 2012). 
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1.2.2 Chronic inflammation 
Chronic inflammation is of a more prolonged duration and manifests 
histologically by the presence of lymphocytes and macrophages, resulting in fibrosis 
and tissue necrosis. The persistent chronic inflammation increases the  development 
of the degenerative  diseases such as rheumatoid arthritis, atherosclerosis, heart 
disease, Alzheimer, asthma, acquired immunodeficiency disorder (AIDS), cancer, 
congestive heart failure (CHF), multiple sclerosis (MS), diabetes, infections (bacteria, 
fungi, parasites), gout, IBD-inflammatory bowel disease, aging and other 
neurodegenerative CNS depression, all of which are associated with 
immunopathology that appears to play a key role in the onset of the condition 
(O’Byrne and Dalgleish., 2001; Dalgleish and O’Byrne., 2002). 
 
1.3 Aim of the study 
The aim of the study is to investigate antioxidative, analgesic and anti-
inflammatory effects of Acokanthera oppositifolia, Plantago lanceolata, Artemisia 
vulgaris and Conyza canadensis.  
 
1.4 Objectives 
  Evaluate and establish some of the basic ethnopharmaceutical properties of 
Acokanthera oppositifolia, Plantago lanceolata, Conyza canadensis and 
Artemisia vulgaris. 
   Investigate a preliminary phytochemical screening of the plants to rationalise 
their therapeutic usefulness in African traditional medicine.  
  Determine their analgesic, antioxidative and anti-inflammatory effects and 
compare Plantago lanceolata to three other extract plants (Acokanthera 
oppositifolia, Conyza canadensis and Artemisia vulgaris.  
  Evaluate plants toxicity effects in cell cultures by using greiss reagent. 
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CHAPTER 2 LITERATURE REVIEW 
 2.1 Introduction 
Pain is a disabling accompaniment of many medical conditions. Pain control is 
one of the most important therapeutic priorities today. Many analgesic drugs, notably 
opioids and non-steroidal anti-inflammatory drugs (NSAIDs) have their origin in 
natural products that have been used for centuries (Rang et al., 2012).  
 
Inflammation is a normal, protective response to tissue injury caused by 
physical trauma, noxious chemicals or microbiological agents (Kumar et al., 2013). 
There are many inflammatory pathways and the more important are cyclooxygenase 
pathway and lipoxygenase pathway. The use of herbal medicines is fast becoming 
more popular due to toxicity and side-effects of allopathic medicines. Medicinal 
plants play an important role in the development of potent therapeutic agents. There 
are over 1.5 million practitioners in the traditional medicine system using medicinal 
plants in preventive, promotional and curative applications (Kumar et al., 2013). 
 
2.2 Traditional medicine  
2.2.1Herbal medicines 
Herbal medicines are also referred to as herbal remedies, herbal products, 
herbal medicinal products, phytomedicine, phytotherapeutic agents and 
phytopharmaceuticals. The use of herbal medicine in evidence or science-based 
approach to treatment and prevention of diseases is known as phytotherapy. Herbal 
medicines have been  used since time immemorial. Ancient Chinese tests and Indian 
records contain detailed description of the use of a variety of plant-derived 
medications. Even in present days, plants remain the main source of medicines for a 
large proportion of a world’s population, particularly in the developing countries. Over 
the years, synthetic drugs have been plagued by unwanted side-effects, toxicity and 
inefficiency, among other problems (Vadde et al., 2012). In addition, the search for 
new drugs to treat and manage a variety of illnesses through chemical synthesis has 
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not been encouraging. These factors, as well as the emergence of new diseases, the 
proliferation of disorders such as cancers and growing multidrug resistance in 
pathogenic microorganisms have prompted renewed interest in the discovery of 
potential drug molecules from medicinal plants (Vadde et al., 2012). Herbal medicine 
is now globally accepted as a valid alternative system of therapy in the form of 
phytochemicals, and functional foods, a trend recognised and advocated by WHO. 
Though ancient medicinal treatments have been documented, a large number of 
medicinal plants remain undocumented, uncharacterized, with minimal knowledge of 
their use being orally passed from generation to generation (Khare, 2007; Barnes et 
al., 2007; Yang, 2010). 
 
The documentation of medicinal uses of African plants is becoming 
increasingly urgent because of the accelerated loss of the natural habitat of some of 
these plants due to anthropogenic activities. The continent is estimated to have 
216,634,000 hectares of closed forest areas with a calculated annual loss of about 
1% due to deforestation. Many of the medicinal plants become extinct before they 
are even documented.  Africa has one of the highest deforestation rates in the world, 
for example, Cote d’Ivoire and Nigeria have 6.5 and 5% deforestation per year, 
respectively. The rates in these countries are much higher than the global average 
rate of 0.6%. Lack of habitat conservation and protection threatens not only the loss 
of plant resources but also traditional community life, cultural diversity as well as the 
accompanying knowledge of the medicinal value of several endemic plant species 
(Iwu, 2014).  
 
South Africa is blessed with a rich cultural diversity, reflected in the formal and 
informal systems of medicines presently practised in different parts of the country. 
The informal oral-tradition medical systems of the Khoisan people, Nguni and Sotho-
speaking people has not yet been systematised, and are passed on by word of 
mouth from one generation to the next (Van Wyk, 2009). The formal system of 
medicine, which is well documented and systematised, was introduced to the country 
over a period of more than 300 years (since 1652) by Europeans and other settlers, 
and is exemplified by today’s modern Western medicine. Ayurvedic medicine from 
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India, Traditional Chinese medicine and Homeopathic medicine are also commonly 
practised in certain parts of South Africa (Van Wyk, 2009). 
 
2.2.2 Medicinal plants of South Africa 
Medicinal plants are an important aspect of the daily lives of many people and 
an important part of the South African cultural heritage. Southern Africa has well over 
30 000 species of higher plants. The Cape Floral Kingdom alone has nearly 9 000 
species and is the most diverse temperate flora on earth, rivalling the tropical rain 
forest in terms of forest richness. With South Africa’s remarkable biodiversity and 
cultural diversity, it is not surprising to find that approximately 3 000 species of plants 
are used as medicines, with some 350 species are traded in medicinal plants 
markets (Van Wyk, 2009). 
 
Plants were once a primary source of all the medicines in the world and they 
will continue to provide mankind with new remedies. Well-known examples of plants-
derived medicines include quinine, morphine, codeine, aspirin, Atropine reserpine 
and cocaine.  Recently, important anti-cancer drugs such as taxol and vincristine 
have been developed from medicinal plants. South African contribution to world 
medicine includes Cape Aloes (Aloes ferox), Buchu (Agathosma betulina) and 
Devil's Claw (Harpagophytum procumbens). Local equivalents also exist for many of 
the famous remedies used elsewhere. There is a growing interest in natural and 
traditional medicines as a source of new commercial products (Van Wyk, 2009). It is 
clear that traditional healers play an influential role in the lives of African people and 
have the potential to serve as crucial role players in a comprehensive health care 
strategy (Kambizi and Ofolayan, 2001). According to Clarke (1998), traditional 
healers are deeply interwoven into the fabric of cultural and spiritual life, are the first 
health practitioners to be consulted in up to 80% of cases (especially in rural areas), 
and are present in almost every community due to their accessibility in remote areas 
characterised by under developed healthcare facilities (Clarke, 1998).  
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2.2.3 Traditional healing in South Africa 
There are an estimated 200 000 indigenous traditional healers in South Africa, 
and up to 60% of the South African population consults these healers, usually in 
addition to using modern biomedical services (Van Wyk, 2009). Traditional healers in 
South Africa are most commonly known as ‘isangoma’ (Zulu), ‘ixwele’ (Xhosa), 
‘ngaka’ (Sotho), ‘bossiedokter’ (Western and Northern Cape). The term ‘inyanga’ and 
‘sangoma’ are used to refer exclusively to the herbalist and diviner, respectively. In 
modern time the distinction has become blurred, with the healers practicing both 
arts. In addition to herbalists and diviners who are believed to be spiritually 
empowered, there are traditional birth attendants, prophets, spiritual healers, spirit 
mediums, intuitives and dreamers (Van Wyk, 2009). 
 
2.2.4 Other aspects of traditional medicine in South Africa 
Of the nearly 4 000 ethnomedicinal plant taxa used in South African traditional 
healthcare (Arnold et al., 2000), relatively few are considered likely to give rise to 
serious toxicity. Poisoning from traditional medicines is usually a consequence of 
misidentiﬁcation, incorrect preparation or inappropriate administration and toxic 
dosage (Stewart and Steenkamp, 2000), frequently due to self-administration rather 
than innate risks of using traditional healthcare (Popat et al., 2001). Traditional 
healers possess considerable knowledge of medicinal plants and how to avoid acute 
poisoning (Savage and Hutchings, 1987). Several plants used in South African 
traditional medicine can cause damage to genetic material and, therefore, have the 
potential to cause long-term damage in patients when administered as medical 
preparations. The use of the abovementioned plant material for treatment of ailments 
should be treated with caution and rigorous. Toxicological and clinical studies are 
necessary before prescribed in traditional medicine (Stewart and Steenkamp, 2000). 
 
2.3 Some medicinal plants used against pain and inflammation 
About 18% of the world depends on herbal-based alternative systems of 
medicine. An estimated 70 000 plants (including lower plants) are used in medicine. 
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Herbal medicine is now expanding at an astonishing pace due to the great inputs 
from ethnomedicinal practice being pooled from all over the world (Daniel M, 2006). 
African traditional medicine is the oldest and perhaps the most diverse of all 
medicine systems (Daniel M, 2006). The biological and cultural diversity that 
constitute the cradle of mankind (there are more than 2 000 languages in Sub-
Saharan Africa is reflected in the market regional differences in healing practices. 
Unfortunately, the various systems were poorly recorded and remain so to this day 
(Van Wyk and Wink, 2004). 
 
2.3.1 Boophone disticha 
       Boophone disticha: Common names, Century Plant, Poison Bulb, Sore-eye 
Flower, Kxutsana-yanaha Motlasisa (Sesotho) Inkwadi (Xhosa, Zulu); Ibhade (Zulu) 
is an attractive, deciduous bulbous plant with a thick covering of dry scales above 
the ground. The large, round heads are sometimes on such sort terms that they 
appear to grow directly from the bulbs, almost at ground level. The colour of flowers 
are from shades of pink to red and are sweetly scented (July to October). The 
pedicels (flowers stalks) elongate after flowering to form a large seed head. This 
breaks off at the top of the scape (stalks) and tumbles across the veld dispersing the 
seed (Van Der Spuy, 1971). 
        
The greyish green leaves are erect arranged in a conspicuous fan and are usually 
produced after flowering in spring. The bulb is very poisonous. Boophone disticha 
contains extremely toxic alkaloids and several human deaths have been recorded 
(Du Plooy et al., 2001). Boophone disticha has many medicinal uses. The Bushmen 
once used the poison for their arrows, and traditional healers use it to treat pain and 
wounds. Parts of the plant are used by certain African tribes and also by some 
Europeans to cure specific ailments. The outer covering of the bulb is applied to boils 
and abscesses. Fresh leaves are used to stop bleeding and wounds. The name 
‘sore-eye’ flower refers to the fact that if a person is exposed to the open flowers in a 
confined place, it may lead to sore eyes and even to a headache (Van Vyk, 1998; 
Jackson, 1990). 
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2.3.2 Lippia javanica  
       Lippia javanica commonly called fever tea lemon bush (English), Koorsbossie 
Benkesbossie (Afrikaans), inZinziniba (Xhosa), unSuzwane (Zulu) is 1-2 m high 
woody shrub that stands erect. The multistems have a square appearance when 
looked at in cross-section. The leaves are hairy with noticeable veins, giving off a 
lemon-like odour when crushed. It is said to be one of the most aromatic plant of 
South African’s indigenous shrubs. The small cream flowers can be found on the 
shrub from summer to autumn in some areas. These flowers are arranged in dense 
rounded flower heads. The fruits are rather inconspicuous, small and dry (Wan Wyk, 
1998; Van Wyk, 2000). These plants are widespread throughout a large part of 
South Africa, with the exception of the Western Cape. Lippia javanica grows from the 
Eastern Cape Northwards extending into Tropical Africa including Botswana, 
Swaziland, Malawi, Zambia, Tanzania and Kenya. This herb is said to be an effective 
treatment of fever, especially in case of malaria influenza, measles and as 
prophylactic against lung infections. The smoke from the herb has proven to be 
effective, when inhaled against asthma, chronic cough and pleurisy. Skin disorders 
such as heat rash and other rashes, as well as scratches, stings and bites can also 
be treated (Van Wyk, 1997; Fox, 1983). Lippia javanica is rich in volatile oil and 
numerous monoterpenoids have been identified, including myrcene, caryophyllene, 
linalool, p-cymene and ipsdienone. The volatile oil of Lippia javanica has 
decongestant, strong anti-septic effects and anti-inflammatory activity (Van Wyk, 
2009). 
 
2.3.3 Anemone vesicatoria   
2.3.3.1 Plant description 
Anemone vesicatoria (previously known as Knowltonia vesicatoria) is a 
perennial herb with a short rhizome and fleshy roots, usually growing on shady 
slopes and in forests. The leaves are firm-textured, dark green and divided into three 
leaflets. The leaf stalks are purple-red towards their bases. White or yellowish 
flowers are produced in the winter and early spring, followed by small black fleshy 
fruits. Several other known species of Anemone (formerly know Tonia), include 
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Anemone anemonoides (Zulu: "uxaphusa"), Anemone brateata (Zulu: "umvuthaza") 
and Anemone knowltonia (Anemone capensis; Afrikaans: “katjedrieblaar"). The fresh 
leaves are mainly used in medicine, sometimes also the roots. Anemone vesicatoria 
is widely distributed in the western and southern parts of South Africa, mainly in the 
Western Cape (Watt and Breyer-Brandwijk, 1962; Hutchings et al, 1996).  
 
2.3.3.2 Medicinal uses of Anemone vesicatoria 
The plant is an old Cape remedy for lumbago and rheumatism (Forbes, 1986; 
Smith, 1966). Decoctions of the roots, mixed with Pelargonium roots, have also been 
used to treat colds and influenza (Watt and Breyer-Brandwijk, 1962). Fresh leaves 
and roots are bruised and applied to the skin, producing blisters (hence the names 
"vesicatoria" and "brandblaar") (Watt and Breyer-Brandwijk, 1962; Smith, 1966). 
Infusions may be used for the same purpose. Smoke from burning leaves (Hutchings 
et al., 1996) or the fumes from crushed leaves (Watt and Breyer-Brandwijk, 1962) 
may be inhaled for headaches. 
 
2.3.3.3 Active ingredients 
         Many species of the Ranunculaceae family are known to contain irritant, toxic 
yellow oil known as protoanemonin (Bruneton, 1995). When the leaves or roots are 
dried, protoanemonin is rapidely dimerised to form non-toxic anemonin (Bruneton, 
1995). A structurally related glycoside, ranunculin, is found in several members of 
the family. Protoanemonin produces a strong allergic reaction on the skin, resulting 
in blistering. This has an effect similar to mustard oil, which is a powerful irritant and 
has been used as a counter-irritant and rubefacient (Bruneton, 1995). 
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2.4 Plants used in this study 
2.4.1 Plantago lanceolata 
A rosette-forming perennial herb bearing narrowly oblong, sparsely hairy and 
distinctly parallel-veined leaves distinctly ridged flowering stalks and numerous 
inconspicuous white or pale pink flowers in a dense solitary clusters (Van Wyk, 
2004). Plantain is used mainly against catarrhs of the respiratory tract and 
inflammation of the mouth and throat. It is externally used to treat wounds and 
inflammation of the skin. Greater plantain herbs are traditionally used against cystitis, 
haematuria and for relief from irritating and bleeding haemorrhoids. It is used to treat 
colds and flu in Chinese modern herbalism (Van Wyk, 2004). 
 
Plantain draws toxicity from the body. It has a long history of use as a remedy 
for blood poisoning and is considered an ‘alternative blood purifier in the old sense of 
the word. Its rich nutriments stimulate the liver and enrich or ‘cleanse the blood. It is 
used to treat liver problems, poor digestion, hepatitis, jaundice, skin eruption and 
eruptive personality (too much heat in the body). Plantain is the poultice herb 
supreme. The leaves can be chopped, mashed, and placed directly over the problem 
area (Figure 2.1). They can be made into a strong tea, and a cloth soaked in the tea 
is placed directly over the area. As a poultice, plantain is a highly effective remedy 
for bites and insect stings, boils and other eruptive skin disorders and any deep-
seated infection. Plantain has such excellent drawing properties that it can be used 
to remove slivers that are too deep to pull out (Rosemary, 2012).  
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Figure 2.1: Plantago lanceolata (Lam).  
 
  
Plantain also has haemostatic properties, meaning that it can help check 
bleeding. As a tea or tincture, plantain can also be used to stanch heavy menstrual 
bleeding. Though it can be used alone to stop bleeding, it’s more effective when 
blended with yarrow and nettle for this purpose. It’s also an excellent wound healing 
agent shortening recovery time. All parts of plantain are used for medicinal purpose 
mainly seeds, roots, and leaves (Rosemary, 2012). 
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Plantain is nutrient dense, containing proteins, starch, and a host of vitamins 
and can thus serve as an excellent emergency food. Though it can be bitter and 
stringy as it gets older, it’s a tasty ingredient in many wild-food dishes. The plantain 
seeds, which grow at the top of a long slender stalk, are rich in mucilage and mildly 
laxative. A cultivated variety of plantain, Plantago phylum, is grown for its large, 
abundant seed. Psyllium seeds are the main ingredients in metamucil. Plantain is 
safe; no known reactions or harmful side effects (Rosemary, 2012). Plantago 
lanceolata contain irridoid glycosides up to 2.5% of dry weight. The main compound 
is aucubin, accompanied by catalpol and asperuloside, furthermore, 2% mucilage, 
tannins, phenolic acids (chlorogenic and caffeic acid), unidentified saponins and 
flavonoids (Van-Wyk, 2004). 
 
2.4.2 Acokanthera oppositifolia 
       Common names: Bushman’s Poison bush (English); Gewone Gifboom, 
Boesmansgif (Afrikaans); Uhlunguyembe (Zulu); Nthunguyembe (Xhosa). 
 
2.4.2.1 Botanical description 
Acokanthera oppositifolia Lam is an evergreen shrub or small tree (Kupicha, 
1982; Codd, 1963), usually about 2-5 m in height. The leaves are thick and leathery, 
glossy dark green above the paler below, often tinged red, without any hairs but with 
conspicuous veins. The fragrant white flowers are about 10 mm long and in dense 
clusters almost throughout the year (Figure 2.2). The plum-like berries are 10-15 mm 
long turning dark purple at maturity. Leaves and roots are used for medicinal 
purpose (Van Wyk et al., 2009). 
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Figure 2.2: Acokanthera oppositifolia (Lam) Codd (JMK, 2014). 
 
2.4.2.2 Medicinal uses  
The dried leaves (or roots) are used to treat headaches or as a treatment for 
snake bite. Leaf infusions are taken for abdominal pain. Colds, anthrax, and 
tapeworm infestation are also treated with extracts of this plant. Acokanthera species 
are best known as sources of extremely toxic arrows poison (Forbes, 1986). 
 
2.4.2.3 Preparations and dosage  
The leaves are dried, powdered and sniffed, or may be soaked in water and 
the extract used as a nasal spray. As a snake bite treatment, the leaves or roots are 
powdered and applied either directly to the bite or as a paste (Van Wyk et al., 2009). 
 
2.4.2.4 Active ingredients 
The plant is extremely toxic due to a high content of heart glycosides such as 
acovenoside A, with smaller amounts of acolongifloroside K and several other minor 
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constituents. Among these is ouabain, the famous arrow poison from the East Africa 
Acokanthera schimperi (Van Wyk et al., 2009). 
 
2.4.2.5 Pharmacological effects 
Toxic, analgesic and decongestant properties have been ascribed to 
Acokanthera. Ouabain (Strophantin-G) has been used as an injection in congestive 
heart failure (Van Wyk et al., 2009). 
 
2.4.2.6 Distribution 
This species is widely distributed along the western and northern parts of 
South Africa where it occurs in various habitats, from dense forest to open 
savannah, often in rocky places. It is also distributed in Mozambique, Zimbabwe, 
Zambia, DRC, Malawi, Tanzania and Kenya. (Van Wyk et al., 2009). 
 
2.4.3 Artemisia vulgaris 
  Artemisia vulgaris is distributed in Europe, in Africa, in Asia, and in America. 
This plant may have been transported throughout the world by early humans who 
needed it for its medicinal and food value. It can be easily transported as seeds. The 
meaning of Mugwort may be marsh root since it grows near permanent sources of 
water. The scientific name Artemisia comes from Artemis, Greek Goddess of the 
hunt, wild animals, wilderness, childbirth and virginity. Artemis is capable of bringing 
or relieving disease in women (James et al., 2012). The three species of Artemisia 
differ somewhat in appearance, perhaps the result of growing in different habitats for 
thousands of years. Artemisia is easy to grow from seeds and likes shade. The 
perennial plant grows to 2.5 m high and has variably lobed oblanceolate leaves to 1 
to 7 lobes. The leaves can be up to 15 cm long, are green on top and white, 
tomentose on the underside. The stem and roots are woody (Figure 2.3). The 
flowers grow in panicles as small disciform heads, less than 5 mm in diameter, 
contain 5-9 pistillate flowers and 6-25 disk flowers (James et al., 2012). 
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Figure 2.3: Artemisia vulgaris (Lam).  
   
Since ancient times, Artemisia vulgaris has been used for medicinal and 
magical purposes. The main modern use is as an aromatic bitter to treat dyspepsia 
and lack of appetite. It is traditionally considered to be useful medicine for the 
treatment of neuroses, depression, restlessness, insomnia, anxiety and irregular or 
painful menstruation (Van Wyk, 2004). It is also used to treat flatulence, distension, 
colic, diarrhoea, constipation, cramps, worm infestation, hysteria, epilepsy, vomiting, 
menstrual problems, irregular periods and to promote circulation and as a sedative. 
The root has different uses, as a tonic, for psychoneurons, neurasthenia, depression, 
autonomic neuroses, irritability, restlessness, insomnia and anxiety. Artemisia 
vulgaris is described as an abortifacient without discussion of the preparation 
method (Bisset, 2000).  
   
The plant contains many active compounds including the monoterpenes, 
eucalyptol, camphor, linalool, thujone, 4-terpineol, borneol, spathulenol and 21 
others (Bisset, 2000). These monoterpenes are present in the essential oils that 
make up to 0.03%-0.3% of the plant. The plant also contains sesquiterpenes and 
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sesquiterpene lactones such as eudesmane, vulgarin, psilostachyin and 
psilostachlyin C (Bisset, 2000). The plant also contains flavonol glycosides, quarcetin 
3-O-glucoside, rutin and isorhamnetin 3-O-glucoside (Bisset, 2000), coumarins such 
as easculin, umbelliferone, scopoletin, coumarin and 6-methoxy-7-8-methylene-
dioxycoumarin (Bisset, 2000). Polyacetylenes, carotenoids, and pentacyclic 
triterpenes such as sitosterol and stigmasterol have been isolated or reported 
(Bisset, 2000). 
 
2.4.4 Conyza canadensis 
        The genus Conyza belongs to a well-known family called Asteraceae which 
consists of about around 50 species. Some species of this genus are traditionally 
used for a variety of pharmacological applications such as the treatment of smallpox, 
chicken pox, sore throat, ringworm, skin diseases, toothache and bleeding (Shinwari 
et al., 2000). Conyza canadensis is used for rheumatism, antidiarrheal and as 
antihaemorrhoidal (Shahkirullah et al., 2011). Conyza canadensis also have antiviral 
activity (Hakizamungu et al., 1992; Mathiu et al., 2007; Titanji et al., 2008), and 
antibacterial activity (Nisar et al., 2013). Unidentified compounds in chloroform and 
ethylacetate extracts of Conyza canadensis had antifungal activity (Nisar et al., 
2013).   Secondary compounds possessing anti-inflammatory activity were isolated 
from the genus (Figure 2.4) (Manguro et al., 2011; Mohammad et al., 2009).  
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Figure 2.4: Conyza canadensis (Lam) Cronquist. 
 
2.5 Phytochemical analysis of plants 
  The active ingredients in medicinal plants are chemical compounds that act 
directly or indirectly to prevent of treat disease, and maintain health. The active 
compound may be extracted from the plant in a pure form, after which it is identified 
and tested. Natural, plant-based products are becoming increasingly popular 
nowadays. These phytomedicines are sold as extracts or powders in which the 
concentration of the active ingredient are standardised to ensure safety and efficacy 
(Van Wyk et al., 2009). 
 
Medicinal plants contain some organic compounds which produce definite 
physiological action on the human body and these bioactive substances include 
tannins, alkaloids, carbohydrates, terpenoids, steroids and flavonoids. They are of 
great importance to the health of individuals and communities. Many of these 
indigenous medicinal plants are used as spices and food plants. Phenolics have 
been known to possess a capacity to scavenge free radicals. The antioxidant activity 
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of phenolic is principally due to their redox properties, which allow them to act as 
reducing agents, hydrogen donors. Phenolics are especially common in leaves, 
flowering tissues and woody parts, such as stems and barks. Studies have shown 
that they play an important preventive role in the development of cancer, heart 
diseases and ageing related diseases (Anjali and Sheetal, 2013). 
 
2.6 Antioxidative activity 
Antioxidative act as a defence mechanism to protect against oxidative 
damage, and include compounds to remove or repair damage molecules. They can 
prevent or retard the oxidation caused by free radicals, and sufficient intake of 
antioxidants is supposed to protect against certain diseases (Celiktar et al., 2007). 
Free radicals are not only produced naturally in the cell following stress  or 
respiration, but can also emerge as a result of radiation, bacterial and viral toxins, 
smoking, alcohol or physiological or emotional stress. The body produces many 
antioxidant enzymes such as superoxide dismutase, catalase and glutathione 
peroxidase, which neutralize many types of free radicals (Gamiotea-Turro et al., 
2004).  
 
Oxidative stress is a factor for many human diseases, as either a cause or an 
effect. Plants are the source of medication for preventive, curative, protective or 
promotive purpose (Sidhu et al., 2007). However, the natural antioxidant compounds 
become important (Malpure et al., 2006). Several groups of constituents in plants 
have been identified as potentially  health promoting in animal studies, 
including cholesterol lowering factors, antioxidants, enzyme inducers, and others 
(Dragster et al., 2006). Many of these herbal medicines are finding their way into the 
world market as alternatives to prescribed allopathic drugs currently available to treat 
various disorders and ailments (Huang et al., 2005). The rapid increase in the 
consumption of traditional herbal remedies worldwide has been stimulated by 
several observations which have shown their use as alternative medicine. In 
particular, cancer patients are reported to benefit from treatment with herbal 
medicine and survivability in many cases is significantly increased. Plants that are 
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eaten as foods in southern Africa were shown also to provide important health 
beneﬁts in the form of antioxidative activity (Lindsey et al., 2002). 
 
The medicinal value of plants have assumed important dimensions in the past 
few decades owing mainly to the discovery that extracts from plants contain not only 
minerals and primary metabolites but also a diverse array of secondary metabolites 
with antioxidative potential (Akinmoladun et al., 2007). Plant-based antioxidants are 
now preferred over synthetic because of safety concerns (Akinmoladun et al., 2007). 
This factor has inspired the widespread screening of plants for possible medicinal, 
antimicrobial and antioxidative properties (Jayaprakasha et al., 2001). Antioxidative 
substances block the action of free radicals implicated in the pathogenesis of many 
diseases including atherosclerosis, ischemic heart disease, cancer, Alzheimer’s 
disease and in the aging process (Aruoma, 1998).  
 
2.7 Pathways of inflammation 
2.7.1 Cyclooxygenase pathway 
Cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) are 
prostaglandin synthase that catalyse sequential synthesis of prostaglandins G2 
(PGG2) and PGH2 from arachidonic acid through intrinsic COX and peroxidase 
activities (Agarwal et al., 2009). This group includes the traditional (in the historical 
sense) non-steroidal anti-inflammatory drugs as well as newer coxibs that are more 
selective for COX-2 than COX-1. Non-steroidal anti-inflammatory drugs (NSAIDs), 
sometimes called the aspirin-like drugs or antipyretic analgesics are among the more 
widely used of all agents. There are now more than 50 different NSAIDs on the 
global market. These drugs provide symptomatic relief from pain and swelling in 
chronic joint diseases such as occurs in osteo and rheumatoid arthritis, as well as in 
more acute inflammatory conditions such as fractures, sprains, sports and other soft 
tissue injuries (Rang et al., 2012). They find application in the treatment of 
postoperative, dental and menstrual pain. Several NSAIDs available over the counter 
are widely used for other types of minor aches and pains. Virtually all these drugs, 
particularly the traditional NSAIDs, can have significant unwanted effects, especially 
in the elderly. Newer agents have fewer adverse effects (Rang et al., 2012). 
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Prolonged use of NSAIDs is also associated with severe side effects such as gastro- 
intestinal haemorrhage due to COX-1 inhibition (Lee et al., 2003). 
 
While there are differences between individual NSAIDs, their primary 
pharmacology is attributed to the inhibition of COX enzymes, to decrease the 
production of prostaglandins and thromboxane. There are two common isoforms in 
the enzyme, COX-1 and COX-2. While COX-1 and COX-2 are closely related and 
catalyse the same reaction, there are differences in the expression and role of these 
two isoforms. Cyclooxygenase-1 is constitutively expressed in most tissues, 
including blood platelets. It has a 'housekeeping' role in the body, involved in tissue 
homeostasis, the production of prostaglandin (Rang et al., 2012). In contrast, COX-2 
is induced in inflammation activated by the inflammatory cytokines-interleukins (IL)-1 
and tumour necrosis factor (TNF)-1. Then, the COX-2 isoform is mainly responsible 
for the production of the prostanoid mediators of inflammation (Vane and Botting, 
2001). There is also a considerable pool of constitutive COX-2 present in the central 
nervous system (CNS) and some other tissues, although its function at these sites is 
yet to be completely understood (Rang et al., 2012). The new COX-2 selective drugs 
do not seem to be free of risk either since several COX-2 inhibitors cause 
cardiovascular problems (Muklerjee et al., 2001). Steroids have an obvious role in 
treatment of inflammatory diseases but, due to their potential dependency and 
toxicity, there is a strong need for natural products with minimum side effects (Figure 
2.5). 
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Figure 2.5: Cyclooxygenase-1 and cyclooxygenase-2 (Portanova et al., 1996). 
 
Most traditional NSAIDs inhibit both COX-1 and COX-2, although they vary in 
the degree to which they inhibit each isoform. It is believed that the anti-inflammatory 
probably most analgesic and antipyretic actions of the NSAIDs are related to 
inhibition of COX-2, while their unwanted effects, particularly those affecting the 
gastrointestinal tract are largely a result of their inhibition of COX-1 (Rang et al., 
2012). Compounds with a selective inhibitor action on COX-2 are employed 
clinically. COX-2 seems to be an important target in healing and resolution. There is 
also a concern about the cardiovascular effects of all NSAIDs when these are taken 
over a long time (Rang et al., 2012). 
 
While the pharmacological actions of NSAIDs are broadly similar, there are 
exceptions. Aspirin has other quantitatively different pharmacological actions, and 
Paracetamol is an interesting exception to the general NSAIDs ‘stereotype’. While it 
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is an excellent analgesic, and antipyretic, anti-inflammatory activity is slight and 
seems to be restricted to a few specials cases such as inflammation following dental 
extraction (Skjelbred et al., 1984). Paracetamol inhibits prostaglandin biosynthesis in 
some experimental settings (during fever) but not in others.  
 
2.7.1.1 Mechanism of action 
The main actions of non-steroidal anti-inflammatory drugs (NSAIDs) emanate 
from the inhibition of arachidonic acid (AA) oxidation by the fatty acid COXs. These 
are bi functional enzymes, having two distinct catalytic activities. The first, 
dioxygenase step incorporates two molecules of oxygen into the arachidonic (or 
other fatty acid substrate) chain at C11 and C15, giving rise to the highly unstable 
endoperoxide intermediate PGG2 with a hydroperoxy group at C15. A second 
peroxidase function of the enzyme converts PGG2 to PGH2 with a hydroxyl group at 
C15, which can then be transformed in a cell-specific manner by separate 
isomerase, reductase or synthase enzymes into other prostanoids. Both COX-1 and 
COX-2 are heme containing homodimeric oligomeric enzymes linked to intracellular 
membranes. Structurally, the isoforms are similar, both containing a hydrophobic 
channel into which the arachidonic or other substrate fatty acids dock for catalyses 
(Rang et al., 2012). 
 
Most NSAIDs are competitive inhibitors interfering with the initial 
deoxygenation reaction through competition with the normal substrate for the active 
site. They inhibit COX-1 more rapidly, and COX-2 in a more time-dependant manner 
and is often irreversible. To block the enzyme, NSAIDs enter the hydrophobic 
channel, forming hydrogen bonds with an arginine residue in position 120, 
preventing substrate fatty acids from entering into a catalytic domain. However, a 
single amino acid change in the structure of the entrance of this channel in COX-2 
results in a bulky side pocket that is not found in COX-1. This is important in 
understanding why some drugs, especially those with large sulphur-containing side 
groups, are most selective for the COX-2 (Rang et al., 2012). 
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Other actions, besides inhibition of cyclooxygenase they may contribute to the 
anti-inflammatory effects of some NSAIDs. Reactive oxygen radicals produced by 
neutrophils and macrophages are implicated in tissue damage in some degenerative 
conditions. Some NSAIDs have oxygen radical-scavenging effects as well as COX 
inhibitory activity, and thus may decrease tissue damage caused by reactive oxygen 
radicals. Aspirin also inhibits expression of the transcription factor, which has a key 
role in the transcription of the genes for inflammatory mediators (Rang, et al., 2012). 
 
2.7.2 The lipoxygenase pathway 
Lipoxygenases (LOXs) belong to the groups of dioxygenases involved in the 
insertion of one molecule of oxygen at different sites in arachidonic acid (AA). The 
particular site of incorporation of oxygen is tissue and enzyme-specific. 
Lipoxygenases catalyse the oxygenation of poly-unsaturated fatty acid (PUFA) 
containing a 1,4-Cis, cis-pentadiene system, producing a 1-hydroperoxy-2,4-trans, 
cis-pentadine product. Four main types of LOXs with positional specificities occur in 
animal tissues: 5-lypoxygenase, 8-LOX, 12-LOX, and 15-LOX. 5-LOX is found in 
mast cells, macrophages and neutrophils, where if functions in the synthesis of 5-
hydroperoxy eicosatetraenoic acid (5-HPETE) and leukotrienes B4 (LTB4), C4 
(LTC4) and D4 (LTD4).  5-hydroxy eicosatetraenoic acid (5-HETE), a reduced 
product of (5-HPETE) has potent chemotactic activity towards neutrophils, 
eisinophils monocytes and macrophages. Leukotriene C4 (LTC4) and leukotriene D4 
(LTD4) are derived from leukotriene A4 (LTA4) and are bronchoconstrictor 
components of slow-reacting substance of anaphylaxis (SRS-A) (Poeckel and Punk, 
2010). In comparison to histamine, LTC4 and LTD4 are 1000-fold more potent 
bronchoconstrictors and probably extremely important mediators of asthma allergic 
reactions (Chung, 1995). 
 
Three lipoxygenases, 5-LOX, 8-LOX, and 12-LOX have procarcinogenic 
potential, whereas 12-LOX has anticarcinogenic effects. Products of 12R-LOX are 
associated with various skin diseases (Argawal et al., 2009) and 15-LOX products 
are associated with atherosclerosis. The roles of various LOX metabolites in 
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regulating carcinogenesis have been studied. 15-lypoxygenase (15-LOX) is a critical 
regulator of leukaemia cancer stem cells in chronic myeloid leukaemia (CML). 
Treatments of CML with a 5-LOX inhibitor also impair the functions of leukaemia 
cancer stem cells. Inhibition of 5-LOX by vitamin E and benzyl propargyl ether has 
been reported (Poeckel and Punk, 2010).  
 
There are three LOX isozymes, 5-, 12-, and 15-LOX, that have been identified 
in humans with the ability to convert AA into pro-inflammatory hydroperoxy 
eicosatetraenoic acids (HPETEs), 5-, 12-, and 15-HPETE (Kuhn  et al., 2000). In 
contrast to other LOX enzymes, 15-LOX also initiates the synthesis of lipoxins (LXs) 
involved in the resolution phase of inflammation (Serhan C.N et al., 1984). This will 
focus on the role of 5-LOX and synthesis of LTs as targets for permeability leading to 
oedema by contracting endothelial cells (EC) in the microvasculature (Figure 2.6). 
Leukotrienes also play an important role in GI mucus protection (Rioux et al., 1994; 
Vaananen et al., 1992). In addition, they can interact with sensory nerve fibres, 
leading to changes in their excitability and enhanced release of tachykinins. 
Therefore, LTs are important mediators of various inflammatory diseases and 
allergic disorders including asthma, rheumatoid arthritis, inflammatory bowel 
disease, ulcerative colitis, psoriasis and allergic rhinitis (Lewis et al., 1990).  
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Figure 2.6: Arachidonic acid metabolism from phospholipase A2 indicating 
cyclooxygenase and lypoxygenase pathways (Su and O’Connor, 2013). 
 
2.7.3 Nitric oxide 
2.7.3.1 Nitric oxide chemistry 
There are direct chemical reactions that are defined as those in which nitric 
oxide (NO) interacts with biological targets. The most common reaction is between 
NO and haeme-containing proteins. Such reactions are generally rapid, requiring low 
concentrations of NO and most likely account for the majority of the physiological 
effects of NO. The inductive form of nitric oxide synthase (NOS) is the most 
important pro-inflammatory enzyme responsible for increasing the level of NO (Eun-
Jin et al., 2012). Nitric oxide, synthesised from L-arginine through NOS is a short-
lived free radical and a potentially toxic molecule. It functions as an intracellular 
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messenger mediating a wide range of biological functions. To date, three isoforms of 
NOS have been identified. Conversely, indirect effects involve reactive nitrogen 
oxide species. 
 
2.7.3.2 Nitric oxide and inflammation 
There is a large body of evidence that nitric oxide (NO) is involved in several 
inflammatory disorders. Indeed, virtually every cell and many immunological 
parameters are modulated by NO. It has been shown that NO can be pro-
inflammatory (immunostimulatory, anti-apoptotic) or anti-inflammatory 
(immunosuppressive, pro-apoptotic), host-protective or host damaging during 
infections (Giuseppe et al., 2006). 
 
2.8 Mechanism of pain  
2.8.1 Inflammation related pain 
Pain is a subjective experience, hard to define exactly, even though we all 
know what we mean by it. Typically,  it is a direct response to  an untoward event 
associated with tissue damage or stress, such as injury, inflammation or cancer, but 
severe pain can arise independently of any obvious predisposing cause (e.g. 
trigeminal neuralgia), or persist long after the precipitation injury has healed (e.g. 
phantom limb pain). It can also occur as a consequence of brain or nerve injury (e.g. 
following a stroke or herpes infection). Painful conditions of the latter kind, not 
directly linked to tissue injury, are often described as 'neuropathic pains'. They are 
very common and a major cause of disability and distress, and in general they 
respond less well to conventional drugs than do conditions where the immediate 
cause is clear. In these cases, we need to think of pain in term of disordered 
neurone neural function rather than simply as a normal response to tissue injury 
(Rang et al., 2012). 
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2.8.2 Nociceptive Afferent Neurons 
Under normal conditions, pain is associated with impulse activity in small-
diameter (C and Aδ) primary afferent fibres of peripheral nerves. These nerves have 
sensory endings in peripheral tissues and are activated by stimuli of various kinds 
(mechanical, thermal, chemical) (Julius and Basbaum, 2001; Julius and McCleskey, 
2006). The majority of unmyelinated (C) fibres are associated with polymodal 
nociceptive endings and convey a dull, diffuse, burning pain, whereas myelinated 
(Aδ) fibres convey a sensation of sharp, well-localised pain. C and Aδ fibres convey 
nociceptive information from muscle and viscera as well as from the skin. With many 
pathological conditions, tissue injury is the immediate cause of the pain and results 
in the local release of a variety of chemicals that act on the nerve terminals, either 
activating them directly or enhancing their sensitivity to other forms of stimulation 
(Julius and Basbaum. 2001). 
 
2.8.3 Modulation in the nociceptive pathway 
Acute pain is generally well accounted for in term of nociception: An 
excessive noxious stimulus giving rise to an intense and unpleasant sensation. In 
contrast, most chronic pain states are associated aberrations of the normal 
physiological pathway, giving rise to hyperalgesia (an increased amount of pain 
associated with a mild noxious stimulus), allodynia (pain evoked by a non-noxious 
stimulus) or spontaneous pain without any precipitating stimulus (Tracey, 2008).  
 
2.8.4 Transmission of Pain to Higher Centres 
From the dorsal horn, ascending nerve axons travel in the contralateral 
spinothalamic tracts, and synapse on neurons in the ventral and medial parts of the 
thalamus, from which there are further projections to the somatosensory cortex. In 
the medial thalamus in particular, many cells respond specifically to noxious stimuli 
in the periphery, and lesions in this area cause analgesia. Functional brain imaging 
studies in conscious subjects have been performed to localise regions involved in 
pain processing. These include sensory, discriminatory areas such as primary and 
secondary somatosensory cortex, thalamus and posterior parts of insula as well as 
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affective, cognitive areas such as the anterior parts of insula, anterior cingulate 
cortex and prefrontal cortex (Tracey, 2008). 
 
2.8.5 Neuropathic Pain 
Neurological disease affecting the sensory pathway can produce severe 
chronic pain termed neuropathic pain unrelated to any peripheral tissue injury. This 
occurs with central nervous system disorders such as stroke and multiple sclerosis 
or with conditions associated with peripheral nerve damage, such as mechanical 
injury, diabetic neuropathy or herpes zoster infection (shingles). The 
pathophysiological mechanisms underlying this kind of pain are poorly understood, 
although spontaneous activity in damaged sensory neurons, due to overexpression 
or redistribution of voltage-gated sodium channels, is thought to be a factor (Lai et 
al., 2004; Chahine et al., 2005).  
 
The sympathetic nervous system also plays a part, because damaged 
sensory neurons can express α-adrenoceptors and develop sensitivity to 
noradrenaline that they do not possess under normal conditions. Thus, physiological 
stimuli that evoke sympathetic responses can produce severe pain, a phenomenon 
described clinically as sympathetically mediated pain. Neuropathic pain, which 
appears to be a component of many types of clinical pain (including common 
conditions such as back pain and cancer pain, as well as amputation pain), responds 
poorly to conventional analgesic drugs but can be relieved by some antidepressant 
and antiepileptic agents . Potential new targets are discussed at the end of this 
chapter (Chahine et al., 2005). 
 
2.9 Types of analgesics 
Analgesics are divided into the opioids (with similar properties to drugs 
derived from opium, such as Morphine) and non-opioids. Non-opioids include all the 
other analgesics, including paracetamol, nefopam, and also the non-steroidal anti-
inflammatory drugs (NSAIDS), the best known in which is aspirin. The non-opioids 
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are all less powerful as painkillers than the opioids (O’Shaughnessy, 2011). Opioid 
drugs and paracetamol act directly on the brain and spinal cord to alter the 
perception of pain. Opioids act like the endorphins; hormones naturally produced in 
the brain and stop the cell-to-cell transmission of pain sensation (O’Shaughnessy, 
2011). 
 
2.9.1 Opioids analgesics 
Opioids are defined as compounds with effects that are antagonized by 
naloxone. There are three families of opioid peptides, which are derived from large 
precursor molecules, encoded for by separate genes. Pro-opomelanocortin (POMC) 
gives rise to the opioid peptide β-endorphin and a number of other non-opioid 
peptides, including leu-enkephalin and met-enkephalin. Prodynorphin gives rise to a 
number of opioid peptides, which contain leu-enkephalin and their amino terminal 
(e.g. dynorhin A). The peptides derived from each of these three precursor 
molecules have a distinct anatomical distribution in the central nervous system and 
have varying affinity to the different types of opioid receptors. The precise function of 
these opioid peptides in the brain and elsewhere is still unclear (Neal, 2005). 
 
Opioid analgesics are drugs that mimic endogenous opioids peptides by 
causing a prolonged activation of opioid peptides receptors (usually µ-receptors). 
This produces analgesia, respiratory depression, euphoria and sedation. Pain acts 
as an antagonist of respiratory repression that may, however, become a problem if 
the pain is removed, e.g. with a local anaesthetic. Opioids often cause nausea and 
vomiting and antiemetic may be required. Effects of the nerves plexuses in the gut, 
which also possess opioids peptides and receptors, cause constipation, and 
laxatives, are usually required. Continuous treatment with opioids analgesic results 
in tolerance and dependence in addicts. However, in terminally ill patients, a steady 
increase in morphine dosage is not automatic and, if it does occur, is more likely to 
result from progressively increasing pain rather than tolerance. Similarly, the clinical 
concept of dependence is unimportant. Unfortunately, over caution in the use of 
opioid analgesic frequently results in unnecessarily poor pain control in patients 
(Neal, 2005). 
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Some analgesics, such as codeine and dihydrocodeine are less potent than 
morphine and cannot be given in equianalgesic doses because of the onset of 
adverse effects. As a result of this restriction in dosage, they are less likely, in 
practice, to produce respiratory depression and dependence. They are useful in 
controlling mild to moderate pain (Neal, 2005). 
 
2.9.2 Morphine analogues  
Morphine is a phenanthrene derivative with two planar rings and two aliphatic 
ring structures, which occupy a plane roughly at right angles to the rest of the 
molecule. The most important parts of the molecule for the opioid activity are the free 
hydroxyl on the benzene ring that is linked by two carbon atoms to a nitrogen atom. 
Variants of the morphine molecule have been produced by substitution at one or 
both of the hydroxyls (e.g. diamorphine 3,6-diacethylmorphine, codeine 3-
methoxymorphine, and oxycodone). Substitution of a bulky substituent on the 
nitrogen atom introduces antagonist activity to the molecule (e.g. naloxone) (Rang et 
al., 2012). 
 
2.9.3 Non-steroidal anti-inflammatory drugs (NSAIDS) 
Non-steroidal anti-inflammatory drugs (NSAIDS) and opioids are used in 
management of mild to moderate and severe pain respectively. These drugs have 
serious limitations due to the side effects. Opioids cause respiratory depression, 
euphoria, tolerance and dependence while non-steroidal anti-inflammatory drugs 
produce gastrointestinal irritation and renal damage (Howland and Micek, 2006). The 
reign of morphine as the king of narcotic analgesics, is associated with addictive 
properties and numerous side effects which include respiratory depression, 
drowsiness, decreased gastrointestinal mobility, nauseas and several alterations of 
endocrine and autonomic nervous system (Almeida et al., 2001). 
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2.9.3.1 Aspirin 
Used for many years to relieve pain and reduce fever, aspirin also acts to 
reduce inflammation by blocking the production of prostaglandin, which contributes 
to the swelling and pain in inflamed tissue. Aspirin is useful for headaches, 
toothache, mild rheumatic pain, sore throat, and discomfort caused by feverish 
illnesses. Administered regularly, aspirin may also relieve the pain and inflammation 
associated with chronic rheumatoid arthritis (O’Shaughnessy, 2011). Aspirin is a 
weak organic acid that is unique among the NSAIDS in irreversibility acetylating 
cyclooxygenase. The other NSAIDs, including salicylates, are all reversible inhibitors 
of cyclooxygenase. The NSAIDs, including aspirin have three major therapeutic 
actions, namely, they reduce inflammation (anti-inflammation), pain (analgesia), and 
fever (antipyrexia) (Mycek et al., 2000). Aspirin is found in combination with other 
substances in a variety of medicines. It is also used in the treatment of some blood 
disorders, since aspirin helps to prevent abnormal clotting of blood by preventing 
platelets from sticking together. Aspirin, in the form of tablets, dissolved in water 
before being taken, is absorbed into the bloodstream more quickly, thereby relieving 
pain faster than tablets. Soluble aspirin is not, however, less irritant to the stomach 
lining (O’Shaughnessy, 2011). 
 
2.9.3.2 Paracetamol 
 This analgesic is believed to act by reducing the production of prostaglandins 
in the brain. However, paracetamol does not affect production of prostaglandin in the 
rest of the body, so it does not reduce inflammation, although it can reduce fever. 
Paracetamol can be used for everyday aches and pain such as headache, 
toothache, and joint pains (O’Shaughnessy, 2011). As well as being the most widely 
used analgesic, it is one of the safest when taken correctly. It seldom irritates the 
stomach and allergic reactions are rare. However, an overdose can cause severe 
and possibly fatal liver or kidney damage. Its toxic potential may be increased in 
heavy drinkers. The degradative metabolites of paracetamol cause liver toxicity 
(Graham, 2005). 
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CHAPTER 3 MATERIALS AND METHODS 
3.1 Introduction  
The research project was conducted as follows: plants were collected then 
extracted and kept in dose 10 mg/mL in dimethyl sulfoxide (DMSO) at room 
temperature for further experimentations. A couple of week later, qualitative 
phytochemical analysis was done to determine plants chemical constituents of 
Plantago lanceolata. Thereafter, antioxidant activity was done in four plants before 
anti-inflammatory activity (cyclooxygenase-1 and cyclooxygenase-2, and 
lipoxygenase). Nitric oxide analysis was then done before cytotoxicity (in four plant 
materials). 
 
3.2 Plant collection 
Leaves of the four plant species: Acokanthera oppositifolia, Plantago 
lanceolata, Conyza canadensis and Artemisia vulgaris were used in this study. 
Acokanthera oppositifolia was collected in June 2012 from the Lowveld Botanical 
Garden, in Nelspruit. A voucher specimen (PRU/120583/1/adebayoSA) was 
deposited in the Herbarium of University of Pretoria. Plantago lanceolata, Artemisia 
vulgaris and Conyza canadensis were collected in the vicinity of Midrand, 
Johannesburg. A voucher specimen (MosesTUT1, MosesTUT2, and MosesTUT3) 
were deposited in the Herbarium of Tshwane University of Technology. The leaves 
were subsequently dried at room temperature in a ventilated room, milled to a fine 
powder in an atomy mill Polymax (PC-MFC 90 D) and stored in closed containers 
until used. 
 
3.3 Plant extraction 
Plant material (5 g) from each species investigated was separately extracted 
with 20 mL of acetone SMM instruments), ethyl acetate (SMM instruments), 
chloroform (SMM instruments), hexane (Merck), and water in polyester centrifuge 
tubes. The solvents were selected on their solubility. The tubes were vigorously 
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shaken for 30 minutes in an orbital shaker (Velp Scientifica). Tubes were centrifuged 
at 2 000 rpm for 10 minutes and the supernatant was filtered using Whatman No.1 
filter paper before being transferred into pre-weighed glass containers. The solvent 
was removed by evaporation under a stream of air in a fume hood at room 
temperature to produce the dried extract (Eloff, 2004). The extract was reconstituted 
in DMSO (Merck Schuchardt OHG) at the dose of 10 mg/mL and tested in the 
assays. 
 
3.4 Extraction of plant materials for phytochemical analysis 
Plantago lanceolata leaves were air-dried at room temperature 27oC for two 
weeks, after they were ground to a uniform powder. The n-hexane extract was 
prepared by soaking 100 g of the dry powdered ground material in 1 L of n-hexane at 
room temperature for 48 h. The extract was filtered after 48 h through a Whatmann 
filter paper number 42 (125 mm). The extract was then concentrated using a rotary 
evaporator with the water bath set at 40 ℃. The extract was kept in the DMSO at a 
dose 10 mg/mL. 
 
3.4.1 Test for anthraquinones 
0.5 g of the extract was boiled with 10 mL of sulphuric acid and filtered while 
hot. The filtrate was shaken with 5 mL of chloroform. The chloroform layer was 
pipetted into another test tube and 1 mL of dilute ammonia was added. The resulting 
solution was observed for colour changes. 
 
3.4.2 Test for terpenoids 
To 0.5 g of the extract was added to 2 mL of chloroform. Concentrated 
sulphuric acid, 3 mL was carefully added to form a layer. A reddish brown 
colouration for the interface indicated the presence of terpenoids. 
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3.4.3 Test for flavonoids 
Three methods were used to test for flavonoids. First dilute ammonia (5 mL) 
was added to a portion of an aqueous filtrate of the extract. Concentrated sulphuric 
acid (1 mL) was added. A yellow colouration that disappears on standing indicates 
the presence of flavonoids. Second, a few drops of 1% of aluminium solution were 
added to a portion of the filtrate. A yellow colouration indicates the presence of 
flavonoids. Third, a portion of the extract was heated with 10 mL of ethyl acetate 
over a steam bath for three minutes. The mixture was filtered and 4 mL of the filtrate 
was shaken with 1mL of dilute ammonia solution. A yellow colouration indicates the 
presence of flavonoids. 
 
3.4.4 Test for saponins 
To 0.5 g of extract was added 5 mL of distilled water in a test tube. The 
solution was shaken vigorously and observed for a stable persistent froth. The 
frothing was mixed with 3 drops of olive oil and shaken vigorously after which it was 
observed for the formation of an emulsion. 
 
3.4.5 Test for tannins 
      About 0.5 g of the extract was boiled in 10 mL of water in a test tube and then 
filtered. A few drops of 0.1 g ferric chloride was added and observed for brownish 
green or a blue-black colouration. 
 
3.4.6 Test for cardiac glycosides 
To 0.5 g of extract diluted to 5 mL in water 2 mL of glacial acetic acid 
containing one drop of ferric chloride solution was added. This was underplayed with 
1 ml of concentrated sulphuric acid. A brown ring at the interface indicated the 
presence of a deoxysugar characteristic of cardenolides. A violet ring may appear 
below the brown ring, while in the acetic acid layer a greenish ring may form just 
above the brown ring and gradually spread throughout this layer. 
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3.4.7 Test for steroids 
2 mL of acetic anhydride was added to 0.5 mL crude extract of plant sample 
with 2 mL of sulphuric acid. The colour changed from violet o blue or green in 
sample which indicates the presence of steroids.  
 
3.4.8 Test for quinones 
Dilute NaOH was added to 1 mL of crude extract. Blue-green or red 
colouration indicates the presence of quinones. 
 
3.4.9 Test for coumarin 
10% of NaOH was added to the extract and chloroform was added for 
observation of yellow colour, which shows the presence of coumarin. 
 
3.5 1, 1-diphenyl-2-picryl-hydrazyl assay 
The free radical scavenging activity of these plants were measured by 1,1-
diphenyl-2-picryl-hydrazyl (DPPH.) method, modified for working with 96 well plate. 
With this method it was possible to determine the antiradical power of an antioxidant 
by measuring the decrease in the absorbance of DPPH at 517 nm. As a result of the 
colour changing from purple to yellow the absorbance is decreased when the DPPH 
radical is scavenged by an antioxidant through donation of hydrogen to form a stable 
DPPH-H molecule (Matthäus, B., 2002). This method was applied to ethanolic, 
methanolic and aqueous extracts of plants (acetone, ethyl acetate, chloroform and 
hexane). 
 
3.5.1 Plate layout for DPPH assay 
Three plate wells number 1-3 were used for this test. Plate number one, 
contained blank (DMSO A1 to A3), negative control (B1 to B3), vitamin C (C1-3 to 
 
 
40 
 
F1-4) in four serial dilutions, positive control (quecertin G1-3), plants extracts (18 
samples, acetone, ethyl acetate, chloroform, hexane, and water in triplicate, four 
serial dilutions). Then 50 µL of extract sample, negative control, positive control, and 
vitamin C were added to each well. The plate was incubated at room temperature in 
dark for 30 minutes then read on the plate reader at 570 nm. Then, 50 µL of this 
solution was added to 150 µL of extracts of plants. The mixture was shaken 
vigorously and allowed to stand at room temperature for 30 min. Lower absorbance 
of the reaction mixture indicated higher free radical scavenging activity (Oktay et al., 
2003).  
The DPPH scavenging effect calculated using following equation: %DPPH 
scavenging activity = 100- 
𝑠𝑎𝑚𝑝𝑙𝑒−𝑏𝑙𝑎𝑛𝑘
𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒−𝑏𝑙𝑎𝑛𝑘
x100 
       Where blank is the absorbance of the control reaction (containing all reagents 
except the test compound) and sample is the absorbance of the test compound. 
Extract concentration providing 50% inhibition IC50 was calculated using the graph by 
plotting inhibition percentage against extract concentration. Ascorbic acid (Vit C) and 
quecertin were used as positive control. 
 
3.6 Cyclooxygenase-1 and cyclooxygenase-2 assay 
3.6.1 Material used 
Water was used to prepare all enzyme immunoassay (IEA) reagents and 
buffers were deionized and free of trace organic contaminants (‘Ultra-Pure’ available 
for purchase from Cayman, item No 400000), PG screening EIA antiserum (one vial, 
Cayman, item No 414016), PG screening AchE tracer (one vial, Cayman, item No 
414006), PG screening IEA standard (one vial, Cayman item No 414026), EIA buffer 
concentrate 10x (2 vial, Cayman item No 400060), wash buffer concentrate 400x (1 
vial, Cayman item No 400062), polysorbate 20 (1 vial, Cayman item No 400035), 
mouse anti-rabbit IgG  coated plate (1 plate, Cayman item No 400004), 96-well 
cover sheet (one cover, Cayman item No 400012), Elman’s reagent (three vial, 
Cayman item No 400050), reaction buffer 10x (one vial, Cayman item No 460104), 
Cox-1 ovine (one vial, Cayman item No 460100), Cox-2 human recombinant (one 
vial, Cayman item No 460121), Heme (one vial, Cayman item No 460102), 
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arachidonic acid substrate (one vial Cayman item No 460103), potassium hydroxide 
(one vial, Cayman item No 460105), hydrochloric acid (one vial, Cayman item No 
460106), and stannous chloride (one vial, Cayman item No 460107). 
 
3.6.2 Description of Acetylcholinesterase Tracer (ACETM) competitive Enzyme 
Immunoassays (EIAS) 
This assay was based on the competition between PGs and PG-acetyl 
cholinesterase (Ache) conjugate (PG tracer) for a limited agent of PG antiserum. 
Because the concentration of PG tracer is held constant while the concentration of 
PG varies, the amount of PG tracer that was able to bind to the PG antiserum was 
inversely proportional to the concentration of PG in the well. This rabbit-antiserum-
PG (either free or tracer) complex binds to a mouse monoclonal anti-rabbit antibody 
that has been previously attached to the well. The plate was washed to remove any 
unbound reagents and then Elman’s reagent (containing the substrate) was added to 
the well. The product of this enzymatic reaction was a distinct yellow colour and 
absorbed strongly at 412 nm. The intensity of this colour, determined 
spectrophotometric ally, is proportional to the amount of PG tracer bound to the well, 
which is inversely proportional to the amount of free PG present in the well during 
the incubation (Macleod et al., 1987; Parcells et al., 1985). 
 
3.6.3 Performing cyclooxygenase reactions 
The following reagents were added to two test tubes: 970 µL of Reaction 
Buffer, 10 µL of Hemet, and 10 µL of inactive COX-1 or inactive COX-2, 950 µL of 
Reaction Buffer, 10µL of Hemet, and 10 µL of COX-1 to two test tubes, 950 µl of 
Reaction Buffer, 10 µL of Hemet, and 10 µL of COX-1 to six test tubes,  950 µL of 
Reaction Buffer, 10 µL of Hemet, and 10 µL of COX-2 to two test tubes, 950 µL of 
Reaction Buffer, 10 µL of Hemet, and 10 µL of COX-2 to six test tubes, 20 µL of 
inhibitor to the COX-1 and COX-2 inhibitor tubes and 20 µL of Reaction Buffer or 
solvent to the 100% initial activity tubes and vortex. 50 µL of 1 M HCL was added to 
each test tube to stop enzyme catalysis. The test tubes were then removed from the 
water bath and 100 µL of the saturated Stannous Chloride Solution was added to 
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each test tube and vortex. The incubation took five minutes at room temperature. 
Cyclooxygenase-1 and Cyclooxygenase-2 were inactivated by transferring 20 µL of 
each enzyme to a 500 µL microfuge tube and placing the tube in boiling water for 
three minutes.  The inactivated enzymes were used to generate the background 
values.   
 
3.6.4 Preparation of assay-specific reagents  
3.6.4.1 Prostaglandin screening standard 
After dissolving the lyophilized PG Screening EIA Standard (Item No 414026) 
in 1mL of EIA buffer, the concentration of this solution (the bulk standard) was 
10ng/ml. then we stored this solution.  The standard was prepared for use in EIA: 
first eight clean test tubes were numbered 1 through 8.  800 µL EIA buffer was 
aliquot to tube 1 and 500 µL EIA Buffer to tubes two to eight. 200 µL of the bulk 
standard (10 µg/mL) was transferred to tube one and mixt thoroughly. Serial dilutions 
were made. The standard was diluted by removing 500 µL from tube one and placing 
in tube two; mixed thoroughly. 500 µL was removed from tube two and placed into 
tube three; mixed thoroughly.  This process was repeated for tubes four to eight and 
stored for 24 h. 
 
3.6.4.2 Cyclooxygenase reaction dilutions 
Two clean test tubes were obtained and labelled BC1 and BC2; they were 
then aliquot 990 µL of EIA Buffer on each test tube.  10 µL of Background COX-1 
was added to the tube labelled BC1, 10 µL of Background COX-2 to the dilute 
labelled BC2, and mixed thoroughly. Each test tube contains 1: 100 dilution of the 
original sample.  
 
3.6.5 Ninety-six well plate set up for cyclooxygenase reaction dilutions. 
A total of 18 samples were used in triplicate. Each plate contained two blanks 
(BLK), two Non-Specific Binding wells (NSB), two Maximum Binding wells (Bo), one 
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Total Activity well (TA), and an eight point standard curve run in duplicate.  Each 
COX reaction sample was assayed at two dilutions, and each dilution was assayed 
in duplicate. A minimum of one 100% initial activity sample was assayed for both 
COX-1 and COX-2. 
 
3.6.6 Performing of enzyme immunoassay  
100 µL of enzyme immunoassay (EIA) Buffer was added to Non-Specific 
Binding (NSB) wells,  50 µL of EIA Buffer to Maximum Binding (Bo) wells,  50 µL 
from tube eight to both of the lower standard wells (S8), and 50 µL from tube seven 
to all of the next standard wells (S7). This procedure was done until all the standards 
were aliquot. The sample pipette tip was used to aliquot all the standards. 50 µL of 
background sample was added (BC1 and BC2) per well (Artemisia vulgaris in four 
samples, Acokanthera oppositifolia in five samples, Plantago lanceolata in four 
samples and Conyza canadensis in five samples). Each sample was assayed in 
duplicate. 50 µL of COX 100% Initial Activity Samples was added in two dilutions 
with each dilution assayed in duplicate. 50 µL of COX inhibitors samples were added 
per well, each sample at two dilutions with each dilution assayed in duplicate, then 
50 µL of PG screening acetylcholinesterase (AChE) tracer was added to each well 
except the Total Activity (TA) and the Blank (BLK) wells and 50 µL of PG Screening 
EIA Antiserum to each well except the Total Activity (TA), the Non-Specific Binding 
(NSB), and the Blank (BLK) wells. Each plate was covered with plastic film (Item No 
400012) and incubated for 18 h at room temperature on an orbital shaker.  
 
3.6.7 Development and reading of the plate 
When ready to develop the plate, one DTN vial of Elman’s reagent was 
reconstituted (Item No 400050) with 20 mL of Ultra-Pure water. This Reagent was 
sufficient to develop 100 wells. Empty the wells and rinse five times with Wash 
Buffer. 200 µL of Elman’s reagent was added to each well, and 5 µL of Tracer to the 
Total Activity wells. The plate was covered with plastic film. Optimum development 
was obtained by using an orbital shaker equipped with a large, flat cover to allow the 
plate to develop in the dark in 60-90 minutes.  The bottom of the plate was wiped 
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with a clean tissue to remove fingerprints, dirt, etc. The plate cover was removed 
being careful to keep Elman’s reagent from plashing on the cover.  The plate was 
read at the wavelength between 405 and 420 nm. The absorbance was checked 
periodically until the Bo wells had reached a maximum of 0.3 A. U. (Blank 
subtracted). The plate was read when the absorbance of the wells exceeded 1.5, 
wash the plate, add fresh Elman’s Reagent and let it develop again. 
 
3.6.8 Preparation and data calculation 
The following procedure was done for preparation of the data prior the 
graphical analysis. 
Average the absorbance readings from the NSB wells. 
Average the absorbance readings from the Bo wells 
Subtract the NSB average from the Bo average. This was the corrected Bo or 
corrected Maximum Binding. 
Calculate the %B/Bo (%sample or standard Bound/ maximum bound) for the 
remaining wells. To do this, the average NSB absorbance was subtracted from the 
S1 absorbance and divided by the corrected Bo, then multiplied by 100 to obtain 
%B/Bo. The calculations were repeated for S2-S8 and all sample wells. 
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3.7 Lipoxygenase assay 
3.7.1 Kit material supplied 
Lipoxygenase inhibitor screening assay buffer (10X) (1 vial), developing 
reagent 1 (1 vial), developing reagent 2 (1 vial), 15-Lipoxygenase Standard (1 vial), 
arachidonic acid (Substrate)(1vial), linoleic acid (Substrate) (1 vial ), potassium 
hydroxide (1 vial) , 96-well solid plate (colorimetric assay) 1 plate , 96-well cover 
sheet 1 cover.  
 
3.7.2 Material needed but not supplied by cyclooxygenase-1 and cyclooxygenase-2 
kit material 
   A plate reader capable of measuring absorbance between 490-500 nm , 
adjustable pipettor and a repeat pipettor,  a source of pure water. Glass distilled 
water or HPLC-grade water is acceptable hydrogen peroxide (420 µM). 
 
3.7.3 Reagent preparation 
Lipoxygenase Inhibitor Screening Assay Buffer (10X) was Diluted 3 mL of 
Assay Buffer concentrate with 27 mL of HPLC-grade water. This final Assay Buffer 
(0.1 M Tris-HCl, pH 7.4) was used for dilution of samples and the 15-LOX standard 
prior to assaying. When stored at 4 °C, this diluted Assay Buffer was stable for at 
least two months. Chromogen was prepared prior to use by mixing equal volumes of 
Developing Reagent 1 and Developing Reagent 2 in a test tube and vortexing. The 
volume of Chromogen to be prepared was dependent on the number of wells 
assayed, and then we calculated 100 µL for each well. Chromogen was used within 
one hour. 15-Lipoxygenase Standard, a solution of 15-LOX (soybean) was supplied 
as a positive control. Then 10 µL of the supplied enzyme were transferred to another 
vial and diluted with 990 µL of diluted Assay Buffer prior to use, stored on ice, and 
used within one hour. A 90 µL aliquot of the enzyme per well caused a final 
absorbance of approximately 0.19 nm under the standard assay conditions.   
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3.7.4 Arachidonic Acid (Substrate) 
This vial contained a solution of arachidonic acid in ethanol and was stored at 
-20 °C when not being used. After Transferring 25 µL of the supplied substrate to 
another vial, 25 µl of Potassium was added, Hydroxide, vortex, and diluted with 950 
µL of HPLC-grade water achieved a final concentration of 1 mM.  The prepared 
arachidonic acid solution was used within 30 minutes. A 10 µL aliquot yielded a final 
concentration of 100 µM in the wells. NOTE: linoleic acid was used as substrate in 
the assay.  The vial Linoleic Acid (Substrate) contained a solution of linoleic acid in 
ethanol and was stored at -20 °C when not being used.  25 µL of the supplied 
substrate was transferred  to another vial,  25 µL of Potassium Hydroxide was 
added, vortex, and diluted with 950 µL of HPLC-grade water to achieve a final 
concentration of 1 mM.  The prepared linoleic acid solution was used within 30 
minutes. A 10 µL aliquot yielded a final concentration of 100 µM in the wells. NOTE: 
linoleic acid was used as subtract in the assay. This vial contained 0.1 M potassium 
hydroxide (KOH). The reagent was ready to use as supplied.  
 
3.7.5 Plate setup for lipoxygenase assay 
There was no specific pattern for using the wells on the plate. However, it was 
necessary to have some wells (at least two) designated as non-enzymatic controls 
(blanks). The absorbance of these wells was subtracted from the absorbance 
measured in the sample wells. In this experiment, two wells were designated as 
positive controls  
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Figure 3.1:  Ninety-six plates ready for reading after performing anti-lipoxygenase 
activity of eighteen plant extracts. The lipoxygenase test was done at the University 
of Pretoria, Onderstepoort, Faculty of Veterinary Medicine, Department of 
Paraclinical Sciences, Phytomedicine Programme. 
 
3.7.6 Assay procedure 
To achieve the most accurate results, the purified lipoxygenases (LOX) (5-, 
12- or 15- LOX) was used for this assay. The sample was free of particulates to 
avoid interference in the absorbance measurement. In the blank well portion, 100 µL 
of assay buffer was added to at least two wells. To positive control wells (15-LOX 
standard), 90 µL of 15-LOX standard and 10 µL of assay buffer were added to at 
least two wells. In 100% initial activity wells 90µL of lipoxygenase enzyme and 10µl 
of solvent (the same solvent used to dissolve the inhibitor) were added to two wells. 
The 100% initial activity resulted in approximately 10 nmol/min/mL of activity. In 
inhibitor wells, 90 µL of lipoxygenase enzyme and 10 µL of inhibitor were added to 
two wells.  After this the reaction was initiated by adding 10 µl of subtract (linoleic 
acid) to all the wells. Thereafter, the 96-wells plate was put on a shaker for at least 
five minutes. After adding 100 µL of chromogen to all wells to stop enzyme catalysis, 
and develop the reaction, a plate was covered and we placed the 96-wells plate on a 
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shaker for five minutes, then the cover was removed and read in a plate reader (see 
Fig 8). 
 
3.7.7 Data analysis 
The first step was to determine the average absorbance of the blank, 100% 
initial activity (IA), and inhibitor wells, then subtracted the average absorbance of the 
Blank from the average absorbance of the 100% IA and inhibitor wells, and 
determine the percentage inhibition or percentage IA for each inhibitor using one of 
the following equations. 
% inhibition =100- 
𝑠𝑎𝑚𝑝𝑙𝑒−𝑏𝑙𝑎𝑛𝑘
𝑂𝐷 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
 x100 
  Then the percentage inhibition or the percentage initial activity was plot as a 
function of the inhibitor concentration to determine IC50 value (concentration at which 
there was 50% inhibition). 
 
3.8 Nitric oxide assay 
3.8.1 Material used for Nitric Oxide assay 
 Biological safety cabinet (Vivid Air, air filtration and ventilation supplied), 
DMEM medium (Highveld), trypsin (MERCK), foetal calf serum, mouse leukaemic 
macrophages cell line RAW 264.7, sodium nitrite, LPS solution (Escherichia coli), 
penicillin (MERCK), CO2 incubator (Thermo Electron Corporation), Water bath 
(Memmert), ground extract apparatus (Polymix PC-MFC 90 D), microscope 
(Olympus CKX 31), vortex apparatus (Velp Scientifica), pipettes and multi pipettors 
(Thermo Scientific), hot plate (FMH instruments), DMSO (MERCK Schuchardt 
OHG), hemocytometer, cover glass (Marienfeld, Germany), centrifuge (Thermo 
Electron Corporation), tissue culture flask (Greiner Bio-one), disposable serological 
pipettes (5 mL, 10 mL and 25 mL) (Biocom), 25 cm cell scraper (Biofil), centrifuge 
tubes (gamma irradiation). 
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3.8.2 Preparation of growing cells 
Tissue culture is a general term used to cover methodologies for the removal 
of cells, cultures, or organs from an animal or plant and their successive placement 
into an artificial environment favourable for growth. Bacterial, yeast, plants and 
animals cells are often grown in vitro to study how they grow, divide or differentiate, 
how they interact with each other and how they respond to various types of 
mechanical or pharmacological stimuli. Cell culture provides a controlled 
environment which cells can be incubated under defined conditions and treated with 
growth factors, drugs, toxins or mechanical stimuli in a reproducible fashion (Bonner 
and Hargreaves, 2011). 
 
Upon receiving cells the first day, cells were thawed before use, medium was 
added before centrifuge, then medium supernatant was removed before fresh 
medium was added, cells were suspended once again and seeded into a culture 
flask. Two days later, the medium was removed, cells had attached, new media was 
added, and this was repeated until cells were attached. From one million cells in 
concentration millilitres medium, 10 mL was added, viewed and incubated. The 
medium was changed the day after and allowed growing Vero cells once again by 
decanting added medium and washing cells carefully by shacking slightly, then new 
medium was added to the top side so that cells were not disturbed, 10 mL medium 
was added, cells incubated till they reached 70-80% (ready for sub culturing in 
bigger 75 cm2 flask.  
 
3.8.3 Sub culturing cells 
The lamina floor (Vivid Air) was cleaned thoroughly with 70% ethanol before 
experiments, then everything needed (medium, FBS, and trypsin) was prepared. 
Five minutes later, Vero cells were removed from incubator. Then cells were washed 
twice gently in PBS, 2 mL of trypsin was added then cells were allowed to incubate 
at 37 + 5% CO2 incubator for five minutes. After cells were suspended they were 
transferred into a centrifuge tube to spin at 200 rpm for 10 minutes, thereafter, 
trypsin cell suspended in 2 mL of medium was first removed, and then cells were 
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transferred in a bigger flask (75 cm2) containing 30 mL in medium. Cells culture was 
allowed to incubate till next use. 
 
3.8.4 Cells counting 
After removing cells from the incubator and aspirating off the media, they 
were scraped from the walls of the flask, and then put into a sterile centrifuge tube. 
They were spin in 10000 rpm for 10 minutes, and then the supernatant was 
removed. Medium + PBS were prepared (after warming them). Then 19 ml of 
medium plus 1 mL of PBS were prepared. The total volume obtained was 20 mL (5% 
PBS).  153 µL were removed from the prepared medium in which 153 µL was added 
to stock cells then vacuum.  That small volume of cells was transferred to an 
eppendorf. A new eppendorf was prepared with 20 µL typan blue. A 1:1 dilution was 
prepared by mixing 20 µL of cells with 20 µL of typan blue (dilution factor is 2). Then 
10 µL typan blue cells was transferred and mixed. The haemocytometer was 
cleaned, and the cover slip was added.  10 mL of mixture was added to both sides of 
the Haemocytometer. After all the final preparation was observed and counted with 
haemocytometer into microscope. 
 
3.8.5 Nitric oxide performing  
3.8.5.1 Nitric oxide inhibitory assay in lipopolysaccharide-activated mouse leukaemic  
monocyte macrophage cell line (RAW 264.7 Macrophages) 
        Macrophage culture (the murine MF cell line RAW 264.7) was grown in DMEM 
supplemented with 10% heated-inactivated FCS (foetal calf serum) and 5.5 mL of 
PSF (Penicillin/Streptomycin/Fungizone) to confluence at 37 ºC in a humidified 
incubator of 5 % CO2. For some experiments, cells were starved, which means that 
cells were washed with phosphate-buffered saline (PBS) and incubated in DMEM 
supplemented with FCS and PBS. Experimental design Cells were plated in 96 well 
plates (for nitrite [NO2-] or urea measurements) at 5 × 105 cells/well. When the cells 
fully adhered after starvation for 12 hours, they were exposed to our eighteen 
samples as follow: Acokanthera oppositifolia (acetone, chloroform, ethylacetate, 
hexane and water), Plantago lanceolata (acetone, chloroform, ethyl acetate, hexane, 
 
 
51 
 
and water), Artemisia vulgaris (acetone, chloroform, ethyl acetate and hexane), and 
Conyza canadensis (acetone, chloroform, ethyl acetate, and hexane) respectively 
(50 µL each). 50 µL of LPS was added at a final concentration of 40 µg/mL in 
DMEM. Then the 96 well plates were incubated for 24h. At the scheduled time 
points, the supernatant from the cells stimulated by extract plants samples was 
collected for NO2- measurement using the colorimetric Griess reaction (Green et al., 
1982).  The best incubation time was determined by the preceding time points.  After 
incubation, measurement of NO2- was done for our 18 plants samples and 
measurement of urea was done for plants extract samples to determine the best 
concentration for stimulus. Optimal concentrations plant extracts samples, as 
determined by the earlier experiments, were used to determine the best times. The 
production of NO was measured by determining NO2- in the culture supernatants 
using the colorimetric griess reaction (Corraliza et al., 1994). Aliquots (60 μL) of cell 
supernatant were combined with an equal volume of griess reagent [1% 
sulphanilamide (Alfa Aesar)/0.1% N-(1-napthyl) ethylenediamine (International 
Laboratory USA) – each in 2.5% H3PO4] in a 96-well plate at room temperature for 
10 minutes, and the absorbance at 550 nm was measured with a Multiscan plate 
reader (Genios, Tencan). Absorbance measurements were averaged and converted 
to μmol/L of NO2- per well using a standard curve of sodium nitrite. 
 
3.9 Cell viability (toxicity) 
The traditional use of plants to treat various illnesses is widespread. Herbs 
have been used for medicinal throughout history. Today herbal and food remedies, 
recommended for the treatment of a variety of diseases, are experiencing increased 
popularity. Hundreds of natural products are available to the consumer although 
some could be potentially toxic when ingested in overdoses or in combination with 
other medications (Santa Maria et al., 1997). 
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3.9.1 Cytotoxicity activity by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-4H tetrazolium 
bromide assay 
 
Mouse leukemic macrophage cell line (RAW264.7) was cultured in DMEM 
supplement with 10% FCS and 1% PSF. The cells were harvested with trypsin-
EDTA and diluted to a suspension in fresh DMEM medium. The cells were seeded in 
96 wells plate with 1 x 105 cells per well and allowed adhering for 1 hour at 37 ℃ in a 
humidified atmosphere containing 5% CO2. The medium was then replaced with 
fresh medium to test our plant samples at various concentrations (2, 10, 30, 100 
µg/L) and then incubated for 48 h. Then we used another 96 well plate and added 
the supernatant for the toxicity test. Cytotoxicity was determined by using the 3-(4, 5-
dimethyl-2-thiazolyl)-2, 5-diphenyl-4H tetrazolium bromide (MTT) calorimetric 
method.  
 
 
After 48h incubation with test samples, MTT solution (10 µL, 5 mg/mL in PBS) 
were added to all the wells. After two hours incubation, the medium was removed. 96 
wells plate was filled as follows: blank (DMEM medium + 10 µL MTT + 100 µL cells + 
50 µL LPS), control (medium +10 µL MTT + sample + 100 µL cells + 50 µL LPS), 
sample (medium + 100 µL cells +10 µL sample + 50 µL LPS), standard (medium + 
100 µL cells + 50 µL quecertin + 50 µL LPS). After two hours incubation, the medium 
was removed and Isopropanol was added containing 0.04 M HCL to dissolve the 
formazan production in the cells. To measure optical density of formazan solution 
with a microplate reader at 570 nm, quecertin was used as positive control. The 
stock solution of each sample was dissolved in DMSO and the solution was added to 
the DMEM medium. 
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CHAPTER 4 RESULTS AND DISCUSSION 
4.1 Introduction 
Previous studies demonstrated that Plantago lanceolata has many medicinal 
effects. The leaves of the plant are used as astringent, anti-inflammatory, 
expectorant, topical anodyne, antibacterial, styptic, haemoptysis, haematuria, sore 
throats, coughs, diarrhoea, dysentery, haemorrhoids, cervicitis, rectal fissures, insect 
bites, snake bites, cuts, bruises and abscess (Miser-Salihoglu et al., 2013).  Previous 
studies were done in ethanol or methanol extracts (Miser-Salihoglu et al., 2013). This 
study was designed not only to confirm antioxidant, analgesic and anti-inflammatory 
properties of Plantago lanceolata, but also to compare Plantago lanceolata to 
Acokantera oppositifolia, Conyza canadensis, and Artemisia vulgaris by using 
hexane, ethyl acetate, chloroform, ethanol and water extracts. 
 
4.2 Phytochemical analysis 
Phytochemical screening revealed the presence of anthraquinones, 
phlobatannins, flavonoids, alkaloids, cardiac glycosides, terpenoids, tannins and 
saponins (Table 4.1). The flavonoids, as an anti-oxidant in this plant may contribute 
to the effects of this plant as hepatoprotective and nephroprotective, antimicrobial, 
anti-inflammatory, and anti-carcinogenic effect. Table 1 indicates the phytochemical 
analysis of Plantago lanceolata hexane extract. 
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Table 4.1: Preliminary phytochemical analysis of Plantago lanceolata hexane 
extracts + means positive. – means negative.   
 
Phytochemicals Plantago lanceolata hexane extract  
Anthraquinones                     + 
Terpenoids                      + 
Flavonoids   + 
Saponins   + 
Tannins   + 
Quinones                      - 
Coumarins    - 
Cardiac glycosides    + 
Phlobatannins    + 
Phenols   + 
Alkaloids    + 
 
4.3 Antioxidative test 
The antioxidative activity of Acokanthera oppositifolia, Plantago lanceolata, 
Conyza canadensis and Artemisia vulgaris in acetone, chloroform, ethyl acetate , 
hexane and water, a total of eighteen samples were examined by comparing them 
one another and comparing them to the activity of known antioxidants such as 
ascorbic acid and quecertin with inhibition of DPPH radicals. Substances capable of 
donating electrons/hydrogen atoms are to convert DPPH to their non-radical form 1, 
1’-diphenyl-2-picrylhydrazine, a reaction which can be followed 
spectrophotometrically. On the other hand, the cell walls contain unsaturated fatty 
acids such as linoleic and arachidonic acid. The cell permeability is changed after 
the oxidation of these fatty acids then chronic diseases may occur.  The extension of 
self-life and control of deterioration of fatty foods can be achieved via the protection 
of these acids. Ascorbic acid and quecertin were used as positive control in this test. 
Free radicals scavenging of those four southern Africa medicinal plants were 
investigated. Plantago lanceolata hexane extract indicates the lowest IC50 (0.41 
mg/mL), the same with Plantago lanceolata chloroform extract (0.41 mg/mL). It is 
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important to note that the lower IC50 value reflects better protective action.  Table 4.2 
and Figure 4.1 indicate that among the 19 samples, Plantago lanceolata hexane 
extract and chloroform extract indicate the lowest IC50 and closer to the positive 
control ascorbic acid and quacertin than the other samples. The antioxidative activity 
of the hexane and chloroform extract could be attributed to content of flavonoids.  
Besides, phenolic compounds and flavonoids are also widely distributed in plants 
which have been reported to exert many biological effect, including antioxidative, 
free radical scavenging abilities, anti-inflammatory, and anticarcinogenic (Miller, 
1996). 
 
Table 4.2:  Antioxidative test results of plant extracts. Data represent the percentage 
of inhibition and IC50 (µg/mL) in concentrations mg/ml.  
 
Plant species H20 Acetone Ethyl 
acetate 
Chloroform Hexane 
Artemisia vulgaris ND 2.10 2.20 1.36 3.51 
Acokanthera oppositifolia 2.23 0.54 1.81 0.87 2.42 
Plantago lanceolata 1.81 2.02 0.56 0.41 0.41 
Conyza Canadensis 0.56 0.87 2.42 2.23 2.02 
Vitamin C IC50 = 0.04 mg/ml; Quecertin IC50 = 0.06 mg/ml; ND, not done. 
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Figure 4.1: Antioxidative activity of Acokanthera oppositifolia, Plantago lanceolata, 
Conyza canadensis, and Artemisia vulgaris.  
 
4.4 Anti-inflammatory activity 
4.4.1 Cyclooxygenase-1 and cyclooxygenase-2 test 
   Cyclooxygenase enzymes (COXs, prostaglandin endoperoxide synthases) 
catalyse two reactions, the first being a cyclooxygenase function consisting of the 
addition of molecular oxygen to arachidonic acid (AA) to form prostaglandin G2 
(PGG2). The second is the conversion of PGG2 to PGH2 by a peroxidase function. 
Hence, this COX enzyme performs the critical initial reaction in the AA metabolic 
cascade leading to the formation of pro inflammatory prostaglandins, thromboxane 
and prostacyclin. Prostaglandins regulate smooth muscle contractility, blood 
pressure and platelet aggregation and mediate pain and fever. Inhibition of 
cyclooxygenase activity is the mechanism by which non-steroidal anti-inflammatory 
drugs (NSAIDs) exert their analgesic, antipyretic, anti-inflammatory, and 
antithrombotic effects (Lee et al., 2003). The constitutive form COX-1 is responsible 
for the maintenance of physiological prostanoid biosynthesis. In contrast, COX-2 is 
an inducible isoform linked to inflammatory cell types and tissues. Prolonged use of 
NSAIDs is also associated with severe side effects such as gastro- intestinal 
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haemorrhage due to COX-1 inhibition (Lee et al., 2003). The new COX-2 selective 
drugs do not seem to be free of risk either since several COX-2 inhibitors has been 
found to cause cardiovascular problems (Mukherjee et al., 2001). Steroids have an 
obvious role in the treatment of inflammatory diseases but, due to their toxicity, they 
can only be used over short periods of time except in very serious cases for which 
the risks are acceptable. Consequently, there is a strong need for natural products 
with minimum side effects. The percentage inhibitory activity against COX-1 and 
COX-2 by all the plant extracts was reported as percentage inhibition of 
prostaglandin biosynthesis in Fig 8 and Fig 9. Among our four medicinal plants 
(Acokanthera oppositifolia, Plantago lanceolata, Artemisia vulgaris and Conyza 
canadensis), Plantago lanceola hexane extract is the more active fraction and the 
IC50 value (0.2 mg/mL) concentration is even less than the positive control IC50 = 
0.42 mg/mL (quecertin). On the other hand, Figure 4.2 and Figure 4.3 indicate the 
COX-1 and COX-2 activity of our four medicinal plants in percentage inhibition and 
IC50. Plantago lanceolata hexane extract indicates a percentage of inhibition of 7.25 
and IC50 of 68.99 mg/mL. The same extract has an IC50 of 1.96 mg/mL in COX-2  
(Table 4.4) compared to IC50 68.99 mg/mL in COX-1 (Table 4.3). On the other hand, 
the positive control quecertin indicate an IC50 of 4.6 mg/mL (COX-1) and 8.39 mg/mL 
(COX-2) It may be concluded that Plantago lanceolata is a selective COX-2 inhibitor. 
A therapeutic advantage, in relation to selective COX-2 inhibitors, is the low ulcer 
toxicity. Vane and Botting have suggested a parallel relationship between COX-2 
selectivity and gastrointestinal side effects with NSAID treatment, such that COX-2 
selective compounds cause fewer ulcers (Vane and Botting, 2001). Masferrer (1996) 
demonstrated that administration of COX-2 selective inhibitors did not produce 
stomach lesions, in contrast to administration of nonselective NSAIDs (Masferrer et 
al., 1996).  This indicates its interest in inflammation. 
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Table 4.3: Anti-cyclooxygenase-1 inhibitory of Acokanthera oppositifolia, Plantago 
lanceolata, Conyza canadensis, and Artemisia vulgaris indicating their percentage of 
inhibition and IC50.  
 
Plant species H20 Acetone Ethyl 
acetate 
Chloroform Hexane 
Artemisia vulgaris 
Acokanthera 
oppositifolia 
Plantago lanceolata 
ND 
ND 
ND 
46.00 
62.73 
53.08 
76.67 
57.50 
40.59 
ND 
ND 
ND 
86.25 
46.00 
69.00 
Conyza canadensis ND 40.59 ND ND 40.59 
 
 
Figure 4.2: IC50 values of Acokanthera oppositifolia, Plantago lanceolata, Conyza 
canadensis, and Artemisia vulgaris tested in COX-1 inhibition.  
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Table 4.4: Anti-cyclooxygenase-2 activity of Acokanthera oppositifolia, Plantago 
lanceolata, Conyza canadensis, and Artemisia vulgaris indicating their percentage 
inhibition and IC50.  
 
Plant species H20 Acetone Ethylacetate   Chloroform  Hexane 
Artemisia vulgaris 
Acokanthera oppositifolia 
Plantago lanceolata 
Conyza canadensis 
ND 50.33 
53.93 
1.98 
ND 
      83.89 
     83.89 
> 100 
> 100 
     50.33 
     83.89 
> 100 
    53.93 
  53.93 
> 100 
  1.96 
  ND 
ND 
ND 
ND 
  
 
 
Figure 4.3: IC50 values of Acokanthera oppositifolia, Plantago lanceolata, Conyza 
canadensis canadensis, and Artemisia vulgaris tested in COX-2 inhibition.  
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4.4.2 Lipoxygenase assay 
The lipoxygenase (LOX) activity was performed in four medicinal plants. 
Inhibition of 15-lipoxygenase enzymes by methanol was analysed to evaluate anti-
inflammatory activity. LOX catalyzes dioxygenation of polyunsaturated fatty acids to 
yield cis, trans-conjugated diene hydroperoxides. Results for LOX inhibitory activity 
(IC50) are shown in Figure 4.4. A total of 15 samples were tested for their anti 
lipoxygenase activity three times in triplicate. The first test showed among our 15 
samples, Artemisia vulgaris hexane extract, Plantago lanceolata hexane extract and 
Acokanthera oppositifolia acetone extract were the most active samples with the IC50 
of 4.86, 6.32, and 6.44 mg/mL respectively. The second test was performed with 11 
samples. The third test was performed and 11 samples were used. The three tests 
were summarised in Table 4.4. The highest inhibitory effect was observed for 
Acokanthera oppositifolia acetone extract and Plantago lanceolata hexane extract 
with an IC50 of 4.75 mg/mL and 7.73 mg/mL respectively compared to the positive 
control (quecertin). The results reported here suggest that Acokanthera oppositifolia 
hexane extract and Plantago lanceolata hexane extract has potentially high anti-LOX 
effect, which might be related to the polyphenolic content and antioxidant property of 
the extracts. Lipoxygenase plays an important role in the pathophysiology of several 
inflammatory diseases (Wedi and Kapp, 2001).   
 
Plant derived chemical constituents such as flavonoids, coumarins, quinones, 
pentacyclic triterpenes, sesquiterpenes, alkaloids and polyacetylates have been 
reported to inhibit 15- lipoxygenase (Werz, 2007). Table 4.1 of the primary 
phytochemical analysis of Plantago lanceolata acetone extract indicates the 
presence of flavonoids, coumarins, quinones, and terpenoids. The presence of these 
constituents confirms the potential anti-lipoxygenase activity of Plantago lanceolata. 
Lipoxygenases are sensitive to antioxidants and the most of their action may consist 
of inhibition of lipid hydroperoxide formation due to scavenging of lipidoxy or lipid 
peroxy- radical formed in course of enzyme peroxidation. This can limit the 
availability of lipid hydroperoxide substrate necessary for the catalytic cycle of LOX 
(Govindappa et al., 2011). The results obtained from our studies on these four 
medicinal plants have shown as potential anti-lipoxygenase activity. 
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Figure 4.4: IC50 values of test 1, test 2, and test 3.  
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4.5 Nitric oxide test 
        Nitric oxide (NO) is an important chemical mediator generated by endothelial 
cells, macrophages, neurons, etc. and is involved in the regulation of various 
physiological processes. Excess concentration of NO is associated with several 
diseases.  NO is generated in biological tissues by specific nitric oxide synthesis 
(NOSs), which metabolizes arginine to citralline with the formation of NO via a five 
electron oxidative reaction (Ross, 1993). These compounds are responsible for 
altering the structural and functional behaviour of many cellular components. 
Incubation of sodium nitroprusside solution in PBS at 25 °𝐶 for 2 h resulted in linear 
time dependent nitrite production, which is reduced by the tested extracts of the 
plants. NO scavenging capacity is determined by the decrease in the absorbance at 
550 nm, induced by antioxidants. In order to evaluate the antioxidant potency 
through NO scavenging by the test samples, the change of optical density of NO was 
monitored. Table 4.5 indicates the inhibition of NO production in LPS-activated RAW 
234.7 by our four extracts in different fractions. 
         
 The results of NO scavenging activity of the selected plant extracts are 
shown as amount of NO (µM) and as percentage of NO inhibition Nitric oxide or 
reactive nitrogen species, formed during their reaction with oxygen or with 
superoxide, are very reactive. These compounds are responsible for altering the 
structural and functional behaviour of many cellular components. Conyza canadensis 
acetone extract and Conyza canadensis ethylacetate extract have greater inhibition 
comparative to other plant. The percentage of inhibition of Conyza canadensis 
ethylacetate extract is 94.31 in concentration 10 mg/mL and 96.33 in 100 µg/mL with 
IC50 <2mg/mL. Conyza canadensis acetone extract also indicates a percentage of 
inhibition of 97.31 at concentration 10 mg/mL and an IC50 <2mg/mL. 
         
 The cell viability indicates in Table 4.5 that Conyza canadensis extract 
kills most of cells at the concentrations of 100 and 30 mg/mL (the ethyl acetate 
extract) and in concentrations of 100 and 30 mL/mg (acetone extract). On the other 
hand, Plantago lanceolata indicates an IC50 of 47.66 mg/mL but with good cell 
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viability (91.90 and 100%) at the doses 100 and 30 mg/mL respectively (Table 4.5). 
The primary phytochemical analysis of Plantago lanceolata hexane extract indicates 
the presence of flavonoids and phenols. Phenolic compounds and flavonoids have 
been reported to be associated with antioxidative action in biological systems, acting 
as scavengers of singlet oxygen and free radicals (Rice-Evans et al., 1997; 
Jorgensen et aI., 1999). The nitric oxide scavenging activity of flavonoids and 
phenolic compounds are known (Madson et al., 2000; Jagethia et al., 2004).  
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Table 4.5:  Inhibition of NO production in LPS-activated macrophages RAW 234.7 by Acokanthera oppositifolia, Plantago 
lanceolata, Conyza canadensis and Artemisia vulgaris. 
 
Plant species [Extract] 
(µg/mL) 
IC50 (µg/mL) %   Inhibition of NO 
     H20  Acetone Ethyl 
acetate 
Chloroform Hexane 
Acokanthera 
oppositifolia 
100     ND  86.72±2.25 98.04±1.06 93.27±4.47 86.97±1.97 
30  32.57  ND  37.09±2.44 83.97±4.79 50.62±7.76 39.48±1.52 
10     ND  24.31±2.29 37.22±9.25 21.67±1.83 26.88±1.96 
2     ND  16.47 ±0.94 
 
16.96±5.67 10.35±00 23.33±0.68 
Artemisia 
vulgaris 
100          68.24±2.6  100±1.95  97.19±2.82 98.29±0.96 49.15±2.56 
30     38.32±1.5  96.21±1.21 85.80±2.69 87.21±2.25 29.02±1.20 
10  41.13   24.9±4.68  68.18±3.39 51.84±1.36 53.13±4.50 25.47±1.87 
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2     17.64±9.9  27.79±2.40 23.5±3.461 18.55±7.12 16.35±2.29 
Plantago 
lanceolata 
100         84.4 ± 3.7  93.76±1.17 87.76±7.71 85.74±2.48 84.46±1.26 
30         37.89 ±1.7  51.78±1.73 50.68±5.56 44.13±1.34 38.81±2.19 
10  44.05    21.43 ± 3.6  29.87±2.99 28.10±4.17 26.88±0.48 25.83±1.04 
2     10.66±3.33  21.67±2.01 18.25±1.5 21.67±1.72 18.68±0.78 
Conyza 
canadensis 
100     95.9 ± 2.88  96.88±1.98 96.33±1.17  98.53±0.00 99.20±0.38 
30  53.9 ± 7.04  98.29±1.46 96.94±1.31 97.67±0.57 98.71±0.40 
10  31.71 ±2.26  97.31±1.67 94.31±4.43 80.11±2.64 71.61±0.77 
2 17.69   15.5±6  51.60±1.65 53.80±4.08 48.17±0.69 37.58±1.59 
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Plant species [Extract] 
(µg/mL) 
 IC50 
µg/mL 
   % of cell viability 
 H20  Acetone Ethyl 
acetate 
Chloroform Hexane 
Acokanthera 
oppositifolia 
100     ND  67.98±1.53 48.53±2.60 88.10±4.09 93.33±10.60 
30  32.57   ND  76.94±4.37 88.06±7.27 96.55±1.37 86.82±8.84 
10     ND  86.32±3.28 99.92±8.76 74.30±3.99 83.72±7.39 
2     ND  95.16±2.85 85.78±6.64 80.47±6.80 ND 
Artemisia 
vulgaris 
100    84.46   ±8.17  10.50±1.96 25.00±2.33 40.35±33 59.53±4.16 
30  41.13  81.09 ±5.52  54.96±3.55 73.29±4.17 71.78±0.97 71.63±5.00 
10    70.62 ±6.87  99.34±10.9 91.01±7.83 79.61±3.82 92.09±6.27 
2    74.96 ±4.61  99.76±6.38 94.88±3.70 88.45±1.99 94.92±10.30 
Plantago 
lanceolata 
100    96.36 ±19.86  88.80±8.12 94.84±8.60 75.35±2.44 91.90±7.43 
30    94.92 ±7.20  99.6±10.98 99.16±6.72 91.05±8.87 99.05±10 
10  44.05  99.64 ±11.38  99.57±0.86 99.9±10.81 98.91±4.67 97.93±6.62 
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2    99.37 ±1.42  100±10.10 100±4.98 99.31±3.02 83.99±10.53 
   
 100    85.97 ±9.83  6.20±0.11 5.89±0.05 5.31±0.15 5.70±0.19 
Conyza 
canadensis 
30  17.6  99.65 ±11.29  6.01±0.05 6.67±0.71 54.22±15.80 98.76±2.41 
 10    99.25 ±16.16  89.57±7.91 89.96±8.62 77.21±0.33 98.18±0.46 
 2    100 ±1.06  78.84±8.53 94.2±11.07 99.72±7.78 81.20±0.56 
            
Key: W, water; A, acetone;  E, ethylacetate; C, chloroform, H, hexane. Positive control quecertin IC50 < 2.  Percentage of NO 
inhibition at dose 20µg/mL, 96.71±0.31.  Percentage of cell viability 6.82 ± 0.24 
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4.6 Cytotoxicity test  
Mouse Leukemic macrophage cell line (RAW264.7) was used for the 
cytotoxicity activity by using MTT calorimetric method. The results were combined 
with the nitric oxide table results (Table 4.5). Four plants (Acokanthera oppositifolia, 
Plantago lanceolata, Artemisia vulgaris and Conyza canadensis) were tested; each 
plants in four or five different solvents (acetone, ethylacetate, chloroform, hexane, 
and water). Conyza canadensis ethyl acetate extract kills cells at the dose of 100 
mg/mL and 30 mg/mL with a percentage of cell viability of 5.89 ±0.05  and 
6.67±0.71 respectively. Conyza canedensis chloroform extract is also toxic at the 
dose of 100 mg/mL with a percentage of cell viability 5.31±0.15. Conyza canadensis 
acetone extract indicates a percentage of cell inhibition of 6.20±0.11 and 6.01±0.05 
at doses 100 mg/mL and 30 mg/mL respectively. Table 4.5 also indicates that 
Conyza canadensis is toxic at dose 100 mg/mL. On the other hand, Plantago 
lanceolata indicated a good cell viability with the percentages between 75.35±2.44 
and 100% cell viability. 
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CHAPTER 5 DISCUSSION AND CONCLUSION 
The objectives of this study were to investigate analgesic and anti-
inflammatory activity of Acokanthera oppositifolia, Plantago lanceolata, Conyza 
canadensis and Artemisia vulgaris. The extracts were tested for their antioxidative, 
analgesic, anti-inflammatory activity by determination of inhibitory activity on 
lipopolysaccharides (LPS) induced nitric oxide production in RAW 264.7 cell lines 
using griess reagent, lipoxygenase, COX-1 and COX-2, and cell viability. The plants 
were extracted in five solvents each (acetone, chloroform, ethyl acetate hexane and 
water). A total of ten to twenty samples were used in this study. 
 
For antioxidative activity, the IC50 coefficient was calculated to compare the 
antioxidant activity of individual extracts (Table 4.2). Plantago lanceolata hexane 
extract indicated a higher IC50 (0.41 mg/mL) compared to the other plant extracts 
and to the positive control. On the other hand, phytochemical analysis of the hexane 
Plantago lanceolata hexane extract shows the presence of flavonoids tannins and 
phenols. Flavonoids and Tannins are a major group of compounds that act as 
primary antioxidants or free radical scavengers (Polterait, 1997). Free radical(s) are 
oxygen-centered with at least one unpaired electron and are end products of several 
physiological and biochemical processes. They attack and damage cell membrane, 
cell organelles and DNA resulting in faulty translation of genetic information. This is 
implicated in contributing to cancer, atherosclerosis, aging, immunosuppression, 
inflammation, diabetes, neurodegenerative disorder etc. (Shailasree et al., 2013). 
Phenols are very important plant constituents because of their free radical 
scavenging ability due to their hydroxyl groups (Hatano et al., 1999). The phenolic 
compounds may contribute directly to antioxidant action. It is suggested that 
polyphenolic compounds have inhibitory effects on mutagenesis and carcinogenesis 
in human beings (Tsao and Akhtar, 2005). The antioxidant capacities of the plant 
extracts largely depend on the composition of the extracts. DPPH, scavenging gave 
reliable information concerning the antioxidant ability of the tested compounds 
(Shailasree, et al., 2013). The antioxidative characteristics might be attributed to the 
presence of polyphenolic compounds. Based on the result in the study, it was 
concluded that Plantago lanceolata hexane extract was found to probably have anti-
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oxidant effect. Further studies are required to identify specific active principles of 
these plants for the significant antioxidative effect.   
 
Inflammation is a pathological condition mediated through production of PGE2 
from arachidonic acid (AA) generated by enzyme system PG synthetase, a complex 
enzyme including COX-2. The enzymatic oxygenation of arachidonic acid via the 
COX and LOX pathways play a key role in the mediation of inflammation. As a result, 
the key enzymes of these pathways COX-1, COX-2, and LOX have become the 
target for the development of anti-inflammatory drugs (Kumar, 2011) Another group 
of compounds eliciting inflammatory conditions are leukotrienes which are derived 
directly from AA by enzymatic action of lipoxygenase (LOX) (Shailasree et al., 2012). 
For the anti-inflammatory activity, the plant extracts were tested for their anti COX-1 
and COX-2 activity, anti lipoxygenase activity, and inhibition of LPS 
(Lipopolysaccharides). The enzyme cyclooxygenase-1 (COX-1, prostaglandin 
endoperoxide H synthase-1, PGHS-1), a catalyst of prostaglandin synthesis, has 
been extensively used as a tool for studying the anti-inflammatory effects of plant 
extracts and plant-derived compounds (Bauer, 1996). With the discovery of the 
isoenzyme COX-2, whose production is induced by inflammation mediators, interest 
in cyclooxygenase inhibitors has grown. The adverse effects observed with 
traditional nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and 
indomethacin, are believed to stem from an inhibition of constitutive COX-1 activity, 
and it is hypothesized that selective COX-2 inhibitors exhibit an improved safety 
profile. The constitutive form COX-1 is responsible for the maintenance of 
physiological prostanoid biosynthesis. In contrast, COX-2 is an inducible isoform 
linked to inflammatory cell types and tissues. Prolonged use of NSAIDs is also 
associated with severe side effects such as gastro- intestinal haemorrhage due to 
COX-1 inhibition (Lee et al., 2003). The new COX-2 selective drugs do not seem to 
be free of risk either since several COX-2 inhibitors has been found to cause 
cardiovascular problems (Mukherjee et al., 2001). The Figure 4.2 and Figure 4.3 
indicate the IC50 of the sample extract used in this study. Plantago lanceolata hexane 
extract indicates the lower IC50 in COX-2 inhibition. The IC50 value is close to the 
control (quecertin) compared to the other extract plants. Plantago lanceolata hexane 
extract indicates an IC50 68.99 mg/mL in COX-1 inhibition Table 4.2. This indicates 
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the great interest of the Plantago lanceolata hexane extract by the fact that the 
extract inhibits only the COX-2 enzyme and is without inhibition in COX-1. 
 
The anti lipoxygenase activity was also investigated for the anti-lipoxygenase 
activity. Table 5 indicates that among the four plants, Acokanthera oppositifolia 
hexane extract and Plantago lanceolata hexane extract with an IC50 of 4.75 mg/mL 
and 7.73 mg/mL respectively are the most active extract plants because of their 
lower IC50. Lipoxygenases are sensitive to antioxidants as antioxidants are involved 
in inhibition of lipid hydroperoxide formation due to scavenging of lipidoxy or 
lipidperoxy radicals. This could lead to less availability of lipid hydroperoxide 
substrate required for LOX catalysis (Rackova et al., 2007).  Lipoxygenase are the 
family of the key enzyme in the biosynthesis of leukotrienes which plays an important 
role in the pathophysiology of several inflammatory diseases. Lipoxygenases are 
sensitive to antioxidants and the most of their action may consist of inhibition of lipid 
hydroperoxide formation due to scavenging of lipidoxy or lipidperoxy radicals formed 
in course of enzymatic peroxidation (Kumaraswamy and Satish, 2008). Plantago 
lanceolata inhibited the lipoxygenase enzyme. This indicates that Plantago 
lanceolata may have an interest in anti-inflammation studies.  
 
Nitric oxide (NO) is a potent pleiotropic inhibitor of physiological processes 
such as smooth muscle relaxation, neuronal signalling, inhibition of platelet 
aggregation and regulation of cell mediated toxicity. It is a diffusible free radical that 
plays many roles as an effector molecules in diverse biological systems including 
neuronal messenger, vasodilatation and antimicrobial and antitumor activities 
(Hagerman et al., 1998). Table 4.5 indicates the percentage of inhibition of NO 
production is dose dependent for all the plant extracts as we used an increasingly 
dose of 2, 10, 30 and 100 mg/mL for the nitric oxide test. On the other hand, 
Plantago lanceolata may not be toxic to the cells by the fact that Table 4.5 indicates 
the percentage of cell viability is very high in all the Plantago tests, even in our 
maximum dose used (100 mg/mL). The observed NO scavenging activity of 
Plantago lanceolata hexane extract might be useful for the development of newer 
and more potent natural antioxidants. Observed NO scavenging activity of Plantago 
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lanceolata extract might be useful for the development of newer and more potent 
natural antioxidants. 
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APPENDIX: RAW DATAS 
 
A- Antioxidant analysis 
 
Table: A1 Antioxidant values of samples, controls, blank, and negative 
Conc Sample OD S-
BLANK 
% 
Inhb 
IC 50 
 BLK 0,304 0,000    
 NEG 0,427 0,123    
1 
mg/ml 
VIT C 1 0,133 -0,171 239,16 0,21 
0,5 VIT C 2 0,074 -0,230 286,79 0,17 
0,25 VIT C 3 0,070 -0,234 290,31 0,04 
0,125 VIT C 4 0,077 -0,227 284,57 0,02 
1 QUR 1 0,155 -0,149 220,92 0,23 
0,5 OUR 2 0,167 -0,138 211,69 0,12 
0,25 OUR 3 0,164 -0,141 214,15 0,06 
0,125 QUR 4 0,216 -0,088 171,45 0,04 
10 Art acet 
1 
0,825 0,520 -
322,41 
-1,55 
5 Art acet 
2 
0,456 0,151 -22,90 -10,92 
2,5 Art acet 
3 
0,354 0,050 59,59 2,10 
1,25 Art acet 
4 
0,338 0,034 72,50 0,86 
10 Art 
etOH 1 
1,031 0,727 -
489,93 
-1,02 
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5 Art 
etOH 2 
0,488 0,184 -49,04 -5,10 
2,5 Art 
etOH 3 
0,355 0,051 58,94 2,12 
1,25 Art 
etOH 4 
0,369 0,064 47,71 1,31 
10 Art chl 
1 
0,990 0,685 -
456,45 
-1,10 
5 Art chl 
2 
0,563 0,259 -
110,31 
-2,27 
2,5 Art chl 
3 
0,315 0,010 91,61 1,36 
1,25 Art chl 
4 
0,380 0,076 38,59 1,62 
 
 
Table A1 continue 
Conc Sample OD S-
BLANK 
% 
Inhb 
IC 50 
10 
mg/ml 
Art hex 
1 
0,383 0,079 35,70 14,01 
5 mg/ml Art hex 
2 
0,435 0,130 -5,79 -43,17 
2,5 
mg/ml 
Art hex 
3 
0,384 0,079 35,59 3,51 
1,25 Art hex 
4 
0,469 0,164 -33,37 -1,87 
10 AO 
acet 1 
0,094 -0,210 270,37 1,85 
5 AO 
acet 2 
0,138 -0,167 235,18 1,06 
2,5 AO 0,145 -0,160 229,55 0,54 
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acet 3 
1,25 AOacet 
4 
0,241 -0,063 151,45 0,41 
10 AO 
etOH 1 
0,792 0,487 -
295,64 
-1,69 
5 AO 
etOH 2 
0,308 0,003 97,35 2,57 
2,5 AO 
etOH 3 
0,342 0,038 68,96 1,81 
1,25 AO 
etOH 4 
0,204 -0,101 181,79 0,34 
10 AO chl 
1 
0,621 0,317 -
157,43 
-3,18 
5 AO chl 
2 
0,310 0,006 95,16 2,63 
2,5 AO chl 
3 
0,250 -0,055 144,36 0,87 
1,25 AO chl 
4 
0,217 -0,087 170,61 0,37 
10 AO hex 
1 
0,543 0,238 -93,48 -5,35 
5 AO hex 
2 
0,286 -0,018 114,70 2,18 
2,5 AO hex 
3 
0,364 0,060 51,56 2,42 
1,25 AO hex 
4 
0,338 0,034 72,21 0,87 
10 AO wat 
1 
0,438 0,134 -8,66 -57,73 
5 AO wat 
2 
0,435 0,131 -6,22 -40,16 
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Table A1 continue 
Conc Sample OD S-
BLANK 
% Inhb IC 50 
2,5 AO wat 
3 
0,358 0,054 56,04871 2,23 
1,25 AO wat 
4 
0,360 0,056 54,91204 1,14 
10 PL acet 
1 
0,270 -0,034 127,5778 3,92 
5 PL acet 
2 
0,315 0,011 91,4479 2,73 
2,5 PL acet 
3 
0,351 0,047 61,94858 2,02 
1,25 PL acet 
4 
0,381 0,077 37,42896 1,67 
10 PL 
etOH 1 
0,514 0,210 -70,5007 -7,09 
5 PL 
etOH 2 
0,250 -0,054 144,2219 1,73 
2,5 PL 
etOH 3 
0,153 -0,151 222,977 0,56 
1,25 PL 
etOH 4 
0,128 -0,176 242,8958 0,26 
10 PL chl 
1 
0,051 -0,253 305,2233 1,64 
5 PL chl 
2 
0,053 -0,251 303,6806 0,82 
2,5 PL chl 
3 
0,053 -0,251 303,8972 0,41 
1,25 PL chl 
4 
0,050 -0,254 306,2788 0,20 
10 PL hex 
1 
0,052 -0,252 304,7632 1,64 
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5 PL hex 
2 
0,051 -0,253 305,4127 0,82 
2,5 PL hex 
3 
0,052 -0,252 304,8173 0,41 
1,25 PL hex 
4 
0,051 -0,253 305,521 0,20 
10 PL wat 
1 
0,053 -0,252 304,3572 1,64 
5 PL wat 
2 
0,052 -0,253 305,0609 0,82 
2,5 PL wat 
3 
0,342 0,038 68,95805 1,81 
1,25 PL wat 
4 
0,204 -0,101 181,7862 0,34 
 
Table A1continue 
 
Conc Sample OD S-
BLANK 
% Inhb IC 50 
10 VC acet 
1 
0,621 0,317 -157,429 -3,18 
5 VC 
acet 2 
0,310 0,006 95,15562 2,63 
2,5 VC 
acet 3 
0,250 -0,055 144,3572 0,87 
1,25 VC 
acet 4 
0,217 -0,087 170,6089 0,37 
10 VC 
etOH 1 
0,543 0,238 -93,4777 -5,35 
5 VC 
etOH 2 
0,286 -0,018 114,6955 2,18 
2,5 VC 0,364 0,060 51,55616 2,42 
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etOH 3 
1,25 VC 
etOH 4 
0,338 0,034 72,20568 0,87 
10 VC chl 
1 
0,438 0,134 -8,66035 -57,73 
5 VC chl 
2 
0,435 0,131 -6,22463 -40,16 
2,5 VC chl 
3 
0,358 0,054 56,04871 2,23 
1,25 VC chl 
4 
0,360 0,056 54,91204 1,14 
10 VC hex 
1 
0,270 -0,034 127,5778 3,92 
5 VC hex 
2 
0,315 0,011 91,4479 2,73 
2,5 VC hex 
3 
0,3511 0,0469 61,94858 2,02 
1,25 VC hex 
4 
0,3813 0,0771 37,42896 1,67 
10 VC wat 
1 
0,5142 0,2100 -70,5007 -7,09 
5 VC wat 
2 
0,2498 -0,0545 144,2219 1,73 
2,5 VC wat 
3 
0,1528 -0,1515 222,977 0,56 
1,25 VC wat 
4 
0,1282 -0,1760 242,8958 0,26 
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A2 Cyclooxygenase-1 and cyclooxygenase-2 
Table A21 Cyclooxygenase-1 and cyclooxygenase-2 values for standard plot 
 
  
 
Fig A21 standard curve 
  
 
 
  
  
500
250
125
62.5
31.315.6
y = -2477.5x + 1065.7
R² = 0.9586
0
100
200
300
400
500
600
700
800
900
0 0.1 0.2 0.3 0.4 0.5
Std curve
Conc
Linear (Conc)
std Conc std Conc 
0,097 2000 0,097   
0,149 1000 0,149   
0,245 500 0,245 500 
0,308 250 0,308 250 
0,37 125 0,37 125 
0,423 62,5 0,423 62,5 
0,416 31,3 0,416 31,3 
0,4215 15,6 0,4215 15,6 
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Table A22 Cyclooxygenase-1 values  
 
COX 1   OD-
BLK 
%B/B0 x dil 
factor 
% INHB IC50 
 AV 
acet1 
0,016 1,539 3077,977 10,8695663 46 
 AV 
hex1 
0,012 0,821 1641,588 5,79710203 86,24999 
 AV 
etOH1 
0,013 0,923 1846,786 6,52173978 76,66666 
 AO 
acet1 
0,014 1,129 2257,183 7,97101529 62,72727 
 AO 
hex1 
0,016 1,539 3077,977 10,8695663 46 
 AO 
etOH1 
0,014 1,231 2462,382 8,69565304 57,49999 
 PL 
acet1 
0,015 1,334 2667,580 9,4202908 53,07692 
 PL 
hex1 
0,013 1,026 2051,985 7,24637754 68,99999 
 PL 
etOH1 
0,017 1,744 3488,374 12,3188418 40,58823 
 VC 
acet1 
0,017 1,744 3488,374 12,3188418 40,58823 
 VC 
hex1 
0,017 1,744 3488,374 12,3188418 40,58823 
 QUR1 0,016 1,539 3077,977 10,8695663 4,6 
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Table A23 Cyclooxygenase-2 values 
Samples Cox2  pg/ml   
 OD %B/B0 X Dil 
Factor 
% Inhb IC 50 
AV 
acet2 
0,016 1,539 6155,955 9,93377429 50,33 
AV 
hex2 
0,015 1,436 5745,558 9,27152267 53,93 
AV 
chl2 
0,016 1,539 6155,955 9,93377429 50,33 
AV 
etOH2 
0,013 0,923 3693,573 5,96026458 83,89 
AO 
acet2 
0,015 1,436 5745,558 9,27152267 53,93 
AO 
hex2 
0,011 0,616 2462,382 3,97350972 125,83 
AO 
chl2 
0,013 0,923 3693,573 5,96026458 83,89 
AO 
etOH2 
0,013 0,923 3693,573 5,96026458 83,89 
PL 
acet2 
0,199 39,090 156361,3 252,317867 1,98 
PL 
hex2 
0,201 39,603 158413,2 255,629125 1,96 
PL 
chl2 
0,011 0,616 2462,382 3,97350972 125,83 
PL 
etOH2 
0,011 0,616 2462,382 3,97350972 125,83 
VC 
acet2 
0,014 1,231 4924,764 7,94701944 62,92 
VC 
hex2 
0,016 1,539 6155,955 9,93377429 50,33 
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VC 
chl2 
0,015 1,436 5745,558 9,27152267 53,93 
VC 
etOH2 
0,012 0,718 2872,779 4,63576134 107,86 
QUR2 0,013 0,923 3693,573 5,96026458 8,39 
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A3 Lypoxygenase test 
 
BLK=  BLANK(DMSO)   
QU=  POSITIVE CONTROL 
QUACERTINE 
 
IND=  INDOMETACIN   
NEG=  NEGATIVE CONTROL BORATE 
BUFFER ONLY 
ACA=   ACOKANTHERA 
OPP(ACETONE) 
 
ACC=  ACOKANTHERA 
OPP(CHLOROFORM) 
ACE=  AKOKANTHERA 
OPP(ETHYLACETATE) 
ACH=  ACOKANTHERA 
OPP(HEXANE 
 
ACW=  ACOKANTHERA 
OPP(WATER) 
 
     
PA=  PLANTAGO 
(ACETONE) 
  
PC=  PLANTAGO(CHLOROFORM)  
PE=  
PLANTAGO(ETHYLACETATE) 
 
PH=  PLANTAGO 
(HEXANE) 
  
PW=  
PLANTAGO(WATER) 
  
     
VA=  
VERGERETTE(ACETONE) 
  
VC=  
VERGERETTE(CHLOROFORM) 
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VE=  
VERGERETTE(ETHYLACETATE) 
 
VH=  
VERGERETTE(HEXANE) 
  
VW=  
VERGERETTE(WATER) 
  
     
AA=  ARTEMISIA 
(ACETONE) 
  
AC= Artemisia 
chloroform 
  
AE= ARTEMISIA 
ETHYLACETATE 
  
AH= ARTEMISIA HEXANE   
 
Table A31 Lypoxygenase test value from test 1 
 
Sample OD S-
BLANK 
%inhib Ic50 
blanck 0,872667 0     
Quac 0,921333 0,048667 93,96694 0,532102 
Ind 0,796 -0,07667 109,5041 0,456604 
Neg 0,806667 -0,066     
ACA 1,053333 0,180667 77,60331 6,443024 
ACC 1,116667 0,244 69,75207 7,168246 
ACE 0,947667 0,075 90,70248 5,512528 
ACH 1,098 0,225333 72,06612 6,938073 
ACW 1,254667 0,382 52,64463 9,497645 
PA 1,398667 0,526 34,79339 14,37055 
PC 1,126333 0,253667 68,55372 7,29355 
PE 1,336667 0,464 42,47934 11,77043 
PH 1,041333 0,168667 79,09091 6,321839 
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PW 2,267333 1,394667 -72,8926 -6,85941 
VA 2,089333 1,216667 -50,8264 -9,8374 
VC 1,191 0,318333 60,53719 8,259386 
VE 1,69 0,817333 -1,32231 -378,125 
VH 1,092333 0,219667 72,7686 6,871096 
VW 1,546 0,673333 16,52893 30,25 
AA 1,682667 0,81 -0,41322 -1210 
AC 1,652 0,779333 3,38843 147,561 
AE 1,858667 0,986 -22,2314 -22,4907 
AH 0,849 -0,02367 102,9339 4,857487 
 
 
BLK=  BLANK(DMSO)   
QU=  POSITIVE CONTROL 
QUACERTINE 
 
IND=  INDOMETACIN   
NEG=  NEGATIVE CONTROL BORATE 
BUFFER ONLY 
ACA=   ACOKANTHERA 
OPP(ACETONE) 
 
ACC=  ACOKANTHERA 
OPP(CHLOROFORM) 
ACE=  AKOKANTHERA 
OPP(ETHYLACETATE) 
ACH=  ACOKANTHERA 
OPP(HEXANE 
 
ACW=  ACOKANTHERA 
OPP(WATER) 
 
     
PA=  PLANTAGO 
(ACETONE) 
  
PC=  PLANTAGO(CHLOROFORM)  
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PE=  
PLANTAGO(ETHYLACETATE) 
 
PH=  PLANTAGO 
(HEXANE) 
  
PW=  
PLANTAGO(WATER) 
  
     
VA=  
VERGERETTE(ACETONE) 
  
VC=  
VERGERETTE(CHLOROFORM) 
 
VE=  
VERGERETTE(ETHYLACETATE) 
 
VH=  
VERGERETTE(HEXANE) 
  
VW=  
VERGERETTE(WATER) 
  
     
AA=  ARTEMISA 
(ACETONE) 
  
AC= Artemisa chloroform   
AE= ARTEMISA 
ETHYLACETATE 
  
AH= ARTEMISA HEXANE   
 
Table A32 Lypoxygenase value from test number 2 
 
Sample OD S-
BLANK 
%inhib Ic50 
        
blanck 0,578667    
Quac 0,878333 0,299667 53,89744 0,927688 
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Ind 0,636333 0,057667 91,12821 0,548678 
Neg 0,65 0,071333   
ACA 0,777333 0,198667 69,4359 7,200886 
ACC 0,892333 0,313667 51,74359 9,663033 
ACE 0,944333 0,365667 43,74359 11,43025 
ACH 0,708 0,129333 80,10256 6,241997 
ACW 1,093667 0,515 20,76923 24,07407 
PC 0,815 0,236333 63,64103 7,856567 
PE 1,08 0,501333 22,87179 21,86099 
PH 0,859 0,280333 56,87179 8,791704 
VC 0,853333 0,274667 57,74359 8,65897 
VH 0,920667 0,342 47,38462 10,55195 
 
Table A33 Lypoxygenase value from test number 3 
 
Sample OD S-
BLANK 
%inhib Ic50 
        
blanck 0,603    
Quac 0,851 0,248 59,89218 0,834833 
Ind 0,611 0,008 98,7062 0,506554 
Neg 0,618333 0,015333   
ACA 0,726 0,123 80,10782 6,241588 
ACC 0,769 0,166 73,15364 6,83493 
ACE 1,147667 0,544667 11,91375 41,96833 
ACH 0,730333 0,127333 79,40701 6,296673 
ACW 1,133 0,53 14,28571 35 
PA 1,152667 0,549667 11,10512 45,02427 
PC 0,815333 0,212333 65,66038 7,614943 
PE 1,078333 0,475333 23,12668 21,62005 
PH 0,821333 0,218333 64,69003 7,729167 
VC 0,881667 0,278667 54,93261 9,102061 
 
 
97 
 
VH 0,822667 0,219667 64,47439 7,755017 
AH 0,571 -0,032 105,1752 4,753972 
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A4 Nitric oxide test 
 
Table A41 Nitric oxide values for standard curve 
 
 
 
 
 
 
 
 
Fig A4 standard curve 
  
400 200 100 50 25 12,5 6,25 3,12 1,56 0,78 0,39 0,19
NaNO2 3,507 2,297 1,408 0,762 0,444 0,263 0,164 0,112 0,081 0,07 0,059 0,053
NaNO2 3,519 2,304 1,459 0,853 0,488 0,285 0,175 0,115 0,085 0,067 0,059 0,055
NaNO2 3,833 2,357 1,278 0,694 0,374 0,232 0,153 0,144 0,088 0,064 0,61 0,056
NaNO2 3,645 2,398 1,339 0,731 1,171 0,227 0,39 0,097 0,257 0,062 0,092 0,387
46,14 23,34378 11,80411 6,138222 3,289 1,732111 0,821556 0,429 0,259333 0,144667 0,159111 0,114444
y = 0.1159x
R² = 0.9998
0
10
20
30
40
50
0 100 200 300 400 500
400 46,14 
200 23,3438 
100 11,8041 
50 6,13822 
25 3,289 
12,5 1,73211 
6,25 0,82156 
3,12 0,429 
1,56 0,25933 
0,78 0,14467 
0,39 0,15911 
0,19 0,1444 
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Table A42 Nitric oxide value from plate reading 
 
 
 
  
NITRIC OXIDE ASSAY
Conc. VE VE VE VC VC VC VA VA VA bkVE bkVC bkVA
100 0,082 0,083 0,096 0,073 0,073 0,073 0,097 0,077 0,102 0,067 0,065 0,075
30 0,082 0,087 0,07 0,082 0,083 0,089 0,092 0,079 0,073 0,063 0,072 0,072
10 0,131 0,089 0,074 0,202 0,167 0,181 0,098 0,094 0,077 0,067 0,075 0,075
2 0,351 0,306 0,302 0,35 0,342 0,35 0,34 0,318 0,328 0,068 0,065 0,065
Conc. VW VW VW VH VH VH PH PH PH bkVW bkVH bkPH
100 0,133 0,109 0,095 0,071 0,068 0,066 0,165 0,166 0,151 0,09 0,064 0,076
30 0,368 0,321 0,274 0,08 0,085 0,081 0,41 0,428 0,399 0,07 0,075 0,079
10 0,463 0,445 0,433 0,223 0,216 0,226 0,476 0,488 0,476 0,075 0,067 0,076
2 0,586 0,515 0,511 0,424 0,42 0,404 0,52 0,529 0,529 0,077 0,076 0,083
Conc. PE PE PE PC PC PC PA PA PA bkPE bkPC bkPA
100 0,202 0,115 0,111 0,174 0,155 0,141 0,133 0,132 0,146 0,076 0,079 0,103
30 0,381 0,333 0,308 0,376 0,361 0,377 0,339 0,339 0,359 0,072 0,067 0,083
10 0,488 0,447 0,435 0,474 0,469 0,468 0,485 0,446 0,458 0,065 0,072 0,081
2 0,521 0,5 0,513 0,499 0,511 0,522 0,528 0,503 0,507 0,066 0,084 0,086
Conc. PW PW PW AA AA AA AH AH AH bkPW bkAA bkAH
100 0,202 0,17 0,153 0,066 0,065 0,088 0,339 0,372 0,363 0,09 0,079 0,081
30 0,429 0,413 0,407 0,098 0,084 0,084 0,457 0,464 0,473 0,078 0,068 0,078
10 0,526 0,496 0,478 0,269 0,243 0,224 0,499 0,475 0,481 0,072 0,072 0,079
2 0,538 0,577 0,576 0,487 0,469 0,455 0,559 0,558 0,532 0,077 0,077 0,094
Conc. AE AE AE AC AC AC ACW ACW ACW bk bk bk
100 0,128 0,094 0,097 0,097 0,087 0,099 0,274 0,274 0,244 0,091 0,085 0,091
30 0,169 0,139 0,137 0,156 0,13 0,13 0,43 0,417 0,41 0,071 0,069 0,083
10 0,332 0,335 0,318 0,308 0,36 0,308 0,522 0,466 0,47 0,066 0,07 0,077
2 0,492 0,494 0,453 0,492 0,58 0,505 0,618 0,489 0,53 0,063 0,082 0,097
Conc. ACE ACE ACE ACA ACA ACA ACH ACH ACH bk bk bk
100 0,081 0,076 0,067 0,164 0,135 0,143 0,154 0,17 0,144 0,064 0,075 0,085
30 0,189 0,126 0,148 0,425 0,394 0,401 0,413 0,396 0,414 0,067 0,064 0,078
10 0,479 0,367 0,378 0,5 0,47 0,48 0,469 0,475 0,494 0,066 0,071 0,081
2 0,576 0,511 0,51 0,532 0,523 0,535 0,505 0,514 0,51 0,08 0,075 0,092
Conc. ACC ACC ACC FH2O FH2O FH2O A1 A1 A1 bk bk bk
100 0,154 0,1 0,105 0,262 0,198 0,238 0,285 0,296 0,277 0,083 0,087 0,11
30 0,397 0,296 0,327 0,412 0,388 0,457 0,408 0,414 0,406 0,071 0,08 0,085
10 0,51 0,494 0,486 0,473 0,452 0,458 0,488 0,474 0,453 0,07 0,077 0,09
2 0,58 0,55 0,542 0,547 0,595 0,585 0,532 0,597 0,55 0,069 0,07 0,089
Conc. A16 A16 A16 A20 A20 A20 bk bk bk
100 0,092 0,09 0,079 0,073 0,075 0,064 0,089 0,072 0,085
30 0,242 0,119 0,117 0,216 0,124 0,107 0,1 0,076 0,081
10 0,575 0,341 0,343 0,335 0,353 0,346 0,074 0,071 0,079
2 0,586 0,58 0,551 0,525 0,561 0,551 0,085 0,091 0,161
Conc. Quer Quer Quer CTRL CTRL CTRL bkCTR bkCTR bkCTR bkQuer bkCTR Media
20 0,086 0,083 0,082 0,515 0,506 0,5 0,06 0,064 0,062 0,066 0,053 0,075
5 0,084 0,087 0,084 0,541 0,521 0,516 0,066 0,062 0,064 0,066 0,055 0,077
2 0,2 0,194 0,187 0,553 0,531 0,526 0,065 0,074 0,065 0,065 0,063 0,06
0,5 0,386 0,374 0,4 0,595 0,566 0,54 0,071 0,073 0,072 0,062 0,051 0,077
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Table A43 Amount of nitric oxide produced, average and standard deviation 
 
 
  
Amount of NO produced
Conc. VE VE VE AVG SD VC VC VC AVG SD VA VA VA AVG SD
100 0,129422 0,13805 0,250216 0,17 0,06 0,069025 0,069025 0,069025 0,07 0,00 0,189819 0,017256 0,232959 0,15 0,09
30 0,163934 0,207075 0,060397 0,14 0,06 0,086281 0,094909 0,146678 0,11 0,03 0,172563 0,060397 0,008628 0,08 0,07
10 0,5522 0,189819 0,060397 0,27 0,21 1,095772 0,793788 0,914582 0,93 0,12 0,198447 0,163934 0,017256 0,13 0,08
2 2,44176 2,053494 2,018982 2,17 0,19 2,459016 2,389991 2,459016 2,44 0,03 2,372735 2,182916 2,269198 2,27 0,08
Conc. VW VW VW VH VH VH PH PH PH
100 0,371009 0,163934 0,043141 0,19 0,14 0,060397 0,034513 0,017256 0,04 0,02 0,767903 0,776531 0,64711 0,73 0,06
30 2,571182 2,16566 1,760138 2,17 0,33 0,043141 0,086281 0,051769 0,06 0,02 2,85591 3,011217 2,761001 2,88 0,10
10 3,347714 3,192407 3,08887 3,21 0,11 1,345988 1,285591 1,371872 1,33 0,04 3,451251 3,554789 3,451251 3,49 0,05
2 4,391717 3,77912 3,744607 3,97 0,30 3,002588 2,968076 2,830026 2,93 0,07 3,770492 3,848145 3,848145 3,82 0,04
Conc. PE PE PE PC PC PC PA PA PA
100 1,087144 0,336497 0,301984 0,58 0,36 0,819672 0,655738 0,534944 0,67 0,12 0,258844 0,250216 0,371009 0,29 0,06
30 2,666091 2,251941 2,036238 2,32 0,26 2,666091 2,53667 2,67472 2,63 0,06 2,208801 2,208801 2,381363 2,27 0,08
10 3,649698 3,295945 3,192407 3,38 0,20 3,468507 3,425367 3,416739 3,44 0,02 3,485764 3,149267 3,252804 3,30 0,14
2 3,925798 3,744607 3,856773 3,84 0,07 3,580673 3,684211 3,77912 3,68 0,08 3,813632 3,597929 3,632442 3,68 0,09
Conc. PW PW PW AA AA AA AH AH AH
100 0,96635 0,69025 0,543572 0,73 0,18 -0,11217 -0,12079 0,077653 -0,05 0,09 2,226057 2,510785 2,433132 2,39 0,12
30 3,028473 2,890423 2,838654 2,92 0,08 0,258844 0,13805 0,13805 0,18 0,06 3,27006 3,330457 3,40811 3,34 0,06
10 3,91717 3,658326 3,50302 3,69 0,17 1,699741 1,47541 1,311475 1,50 0,16 3,623814 3,416739 3,468507 3,50 0,09
2 3,977567 4,314064 4,305436 4,20 0,16 3,537532 3,382226 3,261432 3,39 0,11 4,012079 4,003451 3,77912 3,93 0,11
Conc. AE AE AE AC AC AC ACW ACW ACW
100 0,319241 0,025884 0,051769 0,13 0,13 0,103538 0,017256 0,120794 0,08 0,05 1,578947 1,578947 1,320104 1,49 0,12
30 0,845557 0,586713 0,569456 0,67 0,13 0,750647 0,526316 0,526316 0,60 0,11 2,99396 2,881795 2,821398 2,90 0,07
10 2,295082 2,320966 2,174288 2,26 0,06 2,053494 2,502157 2,053494 2,20 0,21 3,839517 3,356342 3,390854 3,53 0,22
2 3,701467 3,718723 3,36497 3,60 0,16 3,537532 4,296808 3,649698 3,83 0,33 4,495255 3,382226 3,735979 3,87 0,46
Conc. ACE ACE ACE ACA ACA ACA ACH ACH ACH
100 0,146678 0,103538 0,025884 0,09 0,05 0,767903 0,517688 0,586713 0,62 0,11 0,595341 0,733391 0,50906 0,61 0,09
30 1,052632 0,50906 0,698878 0,75 0,23 3,114754 2,847282 2,907679 2,96 0,11 2,890423 2,743745 2,899051 2,84 0,07
10 3,563417 2,597066 2,691976 2,95 0,43 3,701467 3,442623 3,528904 3,56 0,11 3,347714 3,399482 3,563417 3,44 0,09
2 4,279551 3,718723 3,710095 3,90 0,27 3,943054 3,865401 3,968939 3,93 0,04 3,563417 3,64107 3,606557 3,60 0,03
Conc. ACC ACC ACC FH2O FH2O FH2O A1 A1 A1
100 0,612597 0,146678 0,189819 0,32 0,21 1,509922 0,957722 1,302847 1,26 0,23 1,509922 1,604832 1,440897 1,52 0,07
30 2,81277 1,941329 2,208801 2,32 0,36 2,864538 2,657463 3,252804 2,92 0,25 2,786885 2,838654 2,769629 2,80 0,03
10 3,796376 3,658326 3,589301 3,68 0,09 3,416739 3,235548 3,287317 3,31 0,08 3,433995 3,313201 3,13201 3,29 0,12
2 4,408973 4,150129 4,081104 4,21 0,14 4,115617 4,529767 4,443486 4,36 0,18 3,822261 4,383089 3,977567 4,06 0,24
Conc. A16 A16 A16 A20 A20 A20
100 0,025884 0,008628 -0,08628 -0,02 0,05 0,008628 0,025884 -0,06903 -0,01 0,04
30 1,225194 0,163934 0,146678 0,51 0,50 1,207938 0,41415 0,267472 0,63 0,41
10 4,322692 2,30371 2,320966 2,98 0,95 2,277826 2,433132 2,372735 2,36 0,06
2 4,322692 4,270923 4,020708 4,20 0,13 3,744607 4,05522 3,968939 3,92 0,13
Conc. Quer Quer Quer CTRL CTRL CTRL
20 0,172563 0,146678 0,13805 0,15 0,01 3,986195 3,908542 3,856773 3,92 0,05
5 0,155306 0,181191 0,155306 0,16 0,01 4,19327 4,020708 3,977567 4,06 0,09
2 1,164797 1,113028 1,052632 1,11 0,05 4,227783 4,037964 3,994823 4,09 0,10
0,5 2,795513 2,691976 2,916307 2,80 0,09 4,693701 4,443486 4,219154 4,45 0,19
4,129997
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Table A44 percentage of nitric oxide inhibition 
 
 
 
  
% of NO inhibition
Conc. VE VE VE AVG SD VC VC VC AVG SD VA VA VA AVG SD
100 97,25 97,06 94,68 96,33 1,17 98,53 98,53 98,53 98,53 0,00 95,96 99,63 95,04 96,88 1,98
30 96,51 95,59 98,71 96,94 1,31 98,16 97,98 96,88 97,67 0,57 96,33 98,71 99,82 98,29 1,46
10 88,25 95,96 98,71 94,31 4,43 76,69 83,11 80,54 80,11 2,64 95,78 96,51 99,63 97,31 1,67
2 48,05 56,31 57,04 53,80 4,08 47,68 49,15 47,68 48,17 0,69 49,52 53,55 51,72 51,60 1,65
Conc. VW VW VW VH VH VH PH PH PH
100 92,11 96,51 99,08 95,90 2,88 98,71 99,27 99,63 99,20 0,38 83,66 83,48 86,23 84,46 1,26
30 45,29 53,92 62,55 53,92 7,04 99,08 98,16 98,90 98,71 0,40 39,24 35,93 41,26 38,81 2,19
10 28,77 32,08 34,28 31,71 2,26 71,36 72,65 70,81 71,61 0,77 26,57 24,37 26,57 25,83 1,04
2 6,56 19,59 20,33 15,49 6,32 36,12 36,85 39,79 37,58 1,59 19,78 18,12 18,12 18,68 0,78
Conc. PE PE PE PC PC PC PA PA PA
100 76,87 92,84 93,57 87,76 7,71 82,56 86,05 88,62 85,74 2,48 94,49 94,68 92,11 93,76 1,17
30 43,27 52,09 56,68 50,68 5,56 43,27 46,03 43,09 44,13 1,34 53,00 53,00 49,33 51,78 1,73
10 22,35 29,87 32,08 28,10 4,17 26,20 27,12 27,30 26,88 0,48 25,83 32,99 30,79 29,87 2,99
2 16,47 20,33 17,94 18,25 1,59 23,82 21,61 19,59 21,67 1,72 18,86 23,45 22,71 21,67 2,01
Conc. PW PW PW AA AA AA AH AH AH
100 79,44 85,31 88,43 84,40 3,73 102,39 102,57 98,35 101,10 1,95 52,64 46,58 48,23 49,15 2,56
30 35,56 38,50 39,60 37,89 1,70 94,49 97,06 97,06 96,21 1,21 30,42 29,14 27,49 29,02 1,20
10 16,66 22,16 25,47 21,43 3,63 63,84 68,61 72,10 68,18 3,39 22,90 27,30 26,20 25,47 1,87
2 15,37 8,21 8,39 10,66 3,33 24,73 28,04 30,61 27,79 2,40 14,64 14,82 19,59 16,35 2,29
Conc. AE AE AE AC AC AC ACW ACW ACW
100 93,21 99,45 98,90 97,19 2,82 97,80 99,63 97,43 98,29 0,96 66,41 66,41 71,91 68,24 2,60
30 82,01 87,52 87,88 85,80 2,69 84,03 88,80 88,80 87,21 2,25 36,30 38,69 39,97 38,32 1,52
10 51,17 50,62 53,74 51,84 1,36 56,31 46,76 56,31 53,13 4,50 18,31 28,59 27,85 24,92 4,68
2 21,25 20,88 28,40 23,51 3,46 24,73 8,58 22,35 18,55 7,12 4,36 28,04 20,51 17,64 9,88
Conc. ACE ACE ACE ACA ACA ACA ACH ACH ACH
100 96,88 97,80 99,45 98,04 1,06 83,66 88,99 87,52 86,72 2,25 87,33 84,40 89,17 86,97 1,97
30 77,60 89,17 85,13 83,97 4,79 33,73 39,42 38,13 37,09 2,44 38,50 41,62 38,32 39,48 1,52
10 24,18 44,74 42,72 37,22 9,25 21,25 26,75 24,92 24,31 2,29 28,77 27,67 24,18 26,88 1,96
2 8,95 20,88 21,06 16,96 5,67 16,11 17,76 15,55 16,47 0,94 24,18 22,53 23,26 23,33 0,68
Conc. ACC ACC ACC FH2O FH2O FH2O A1 A1 A1
100 86,97 96,88 95,96 93,27 4,47 67,87 79,62 72,28 73,26 4,85 67,87 65,85 69,34 67,69 1,43
30 40,15 58,70 53,00 50,62 7,76 39,05 43,46 30,79 37,77 5,25 40,70 39,60 41,07 40,46 0,62
10 19,23 22,16 23,63 21,67 1,83 27,30 31,16 30,06 29,51 1,62 26,94 29,51 33,36 29,93 2,64
2 6,19 11,70 13,17 10,35 3,00 12,43 3,62 5,46 7,17 3,80 18,68 6,74 15,37 13,60 5,03
Conc. A16 A16 A16 A20 A20 A20
100 99,45 99,82 101,84 100,37 1,05 99,82 99,45 101,47
30 73,93 96,51 96,88 89,11 10,73 74,30 91,19 94,31
10 8,03 50,98 50,62 36,54 20,16 51,54 48,23 49,52
2 8,03 9,13 14,45 10,54 2,81 20,33 13,72 15,55
Conc. Quer Quer Quer CTRL CTRL CTRL
20 96,33 96,88 97,06 96,76 0,31 15,19 16,84 17,94
5 96,70 96,14 96,70 96,51 0,26 10,78 14,45 15,37
2 75,22 76,32 77,60 76,38 0,98 10,05 14,09 15,00
0,5 40,52 42,72 37,95 40,40 1,95 0,13 5,46 10,23
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A5 Cytotoxicity test 
Table A51 MTT test values from plate reading 
 
 
 
  
MTT ASSAY
Conc. VE VE VE VC VC VC VA VA VA bkVE bkVC bkVA
100 0,05 0,051 0,051 0,047 0,044 0,046 0,054 0,054 0,052 0,048 0,046 0,05
30 0,065 0,057 0,05 0,612 0,285 0,502 0,052 0,051 0,052 0,052 0,673 0,054
10 0,868 0,766 0,687 0,666 0,666 0,66 0,865 0,738 0,708 0,624 1,299 0,975
2 0,941 0,773 0,717 0,93 0,948 0,798 0,596 0,664 0,774 1,352 1,315 1,321
Conc. VW VW VW VH VH VH PH PH PH bkVW bkVH bkPH
100 0,842 0,741 0,635 0,049 0,051 0,047 0,778 0,719 0,874 0,923 0,049 1,177
30 0,85 1,077 0,902 1,037 0,992 1,035 0,867 0,815 1,209 1,294 1,006 1,579
10 0,985 0,97 0,683 0,98 0,86 1,08 0,863 0,879 0,991 1,76 1,352 1,486
2 0,876 0,862 0,854 0,694 0,696 0,705 0,627 0,696 0,844 1,492 1,537 1,542
Conc. PE PE PE PC PC PC PA PA PA bkPE bkPC bkPA
100 0,77 0,92 0,757 0,657 0,668 0,619 0,689 0,745 0,857 1,288 1,292 1,269
30 0,884 0,918 0,782 0,798 0,868 0,683 0,76 0,934 0,979 1,338 1,344 1,305
10 0,916 1,109 0,908 0,809 0,905 0,838 0,882 0,9 0,89 1,177 1,306 1,217
2 0,938 1,043 0,991 0,912 0,968 0,966 1,055 1,234 1,244 1,104 1,195 1,072
Conc. PW PW PW AA AA AA AH AH AH bkPW bkAA bkAH
100 0,916 0,98 0,59 0,112 0,088 0,071 0,494 0,48 0,562 0,761 0,121 1,078
30 0,824 0,888 0,737 0,515 0,459 0,444 0,606 0,569 0,673 1,039 0,752 1,212
10 0,839 1,043 1,05 0,979 0,833 0,751 0,857 0,725 0,794 1,212 1,16 1,255
2 0,904 0,889 0,874 0,925 0,881 0,793 0,854 0,694 0,901 1,236 1,391 1,374
Conc. AE AE AE AC AC AC ACW ACW ACW bk bk bk
100 0,187 0,225 0,233 0,368 0,364 0,309 0,627 0,775 0,777 0,231 0,281 1,006
30 0,661 0,65 0,58 0,62 0,626 0,606 0,642 0,692 0,758 0,833 0,899 1,193
10 0,857 0,797 0,694 0,696 0,718 0,64 0,548 0,586 0,688 0,958 1,023 1,26
2 0,826 0,849 0,773 0,782 0,76 0,74 0,598 0,641 0,695 1,007 1,217 1,221
Conc. ACE ACE ACE ACA ACA ACA ACH ACH ACH bk bk bk
100 0,437 0,386 0,429 0,602 0,57 0,582 0,728 0,749 0,931 0,254 1,072 0,983
30 0,817 0,784 0,671 0,711 0,654 0,62 0,64 0,812 0,788 1,076 1,208 1,174
10 0,836 0,961 0,781 0,782 0,726 0,719 0,657 0,807 0,696 1,172 1,322 1,328
2 0,776 0,78 0,657 0,848 0,788 0,819 0,814 0,949 0,902 1,354 1,452 1,339
Conc. ACC ACC ACC FH2O FH2O FH2O A1 A1 A1 bk bk bk
100 0,784 0,781 0,708 0,642 0,646 0,772 0,659 0,688 0,704 0,689 0,949 0,994
30 0,823 0,821 0,847 0,855 0,857 0,861 0,744 0,79 0,853 1,355 1,339 1,371
10 0,598 0,637 0,682 0,684 0,64 0,741 0,619 0,678 0,618 1,018 1,392 1,361
2 0,687 0,623 0,766 0,599 0,639 0,636 0,51 0,58 0,55 0,953 1,129 1,131
Conc. A16 A16 A16 A20 A20 A20 DMSO DMSO DMSO bk bk bk
100 0,737 0,272 0,304 0,06 0,056 0,047 0,51 0,572 0,517 0,206 0,062 0,977
30 0,86 0,86 0,777 0,635 0,642 0,734 0,557 0,517 0,514 1,04 1,161 1,07
10 0,972 0,957 0,837 0,807 0,698 0,876 0,598 0,69 0,639 1,264 1,452 1,295
2 0,933 0,98 0,9 0,836 0,756 0,957 0,716 0,653 0,719 1,506 1,67 1,3
Conc. Quer Quer Quer CTRL CTRL CTRL bkCTR bkCTR bkCTR bkQuer Media Media
20 0,059 0,056 0,061 0,76 0,815 0,702 1,325 1,275 1,343 0,052 0,075 0,075
5 0,225 0,249 0,241 0,953 0,859 0,747 1,389 1,39 1,165 0,134 0,075 0,075
2 0,73 0,689 0,776 0,864 1,047 0,962 1,506 1,467 1,524 1,014 0,084 0,084
0,5 0,753 0,723 0,733 0,906 0,85 0,888 1,269 1,582 1,212 0,992 0,086 0,086
0,86 1,37
 
 
104 
 
Table A52 percentage of cell viability 
 
Conc. AVG SD AVG SD AVG SD
100 5,81 5,93 5,93 5,89 0,05 5,47 5,12 5,35 5,31 0,15 6,28 6,28 6,05 6,20 0,11
30 7,56 6,63 5,81 6,67 0,71 71,16 33,14 58,37 54,22 15,80 6,05 5,93 6,05 6,01 0,05
10 100,93 89,07 79,88 89,96 8,62 77,44 77,44 76,74 77,21 0,33 100,58 85,81 82,33 89,57 7,91
2 109,42 89,88 83,37 94,22 11,07 108,14 110,23 92,79 103,72 7,78 69,30 77,21 90,00 78,84 8,53
Conc.
100 97,91 86,16 73,84 85,97 9,83 5,70 5,93 5,47 5,70 0,19 90,47 83,60 101,63 91,90 7,43
30 98,84 125,23 104,88 109,65 11,29 120,58 115,35 120,35 118,76 2,41 100,81 94,77 140,58 112,05 20,32
10 114,53 112,79 79,42 102,25 16,16 113,95 100,00 125,58 113,18 10,46 100,35 102,21 115,23 105,93 6,62
2 101,86 100,23 99,30 100,47 1,06 80,70 80,93 81,98 81,20 0,56 72,91 80,93 98,14 83,99 10,53
Conc.
100 89,53 106,98 88,02 94,84 8,60 76,40 77,67 71,98 75,35 2,44 80,12 86,63 99,65 88,80 8,12
30 102,79 106,74 90,93 100,16 6,72 92,79 100,93 79,42 91,05 8,87 88,37 108,60 113,84 103,60 10,98
10 106,51 128,95 105,58 113,68 10,81 94,07 105,23 97,44 98,91 4,67 102,56 104,65 103,49 103,57 0,86
2 109,07 121,28 115,23 115,19 4,98 106,05 112,56 112,33 110,31 3,02 122,67 143,49 144,65 136,94 10,10
Conc.
100 106,51 113,95 68,60 96,36 19,86 13,02 10,23 8,26 10,50 1,96 57,44 55,81 65,35 59,53 4,16
30 95,81 103,26 85,70 94,92 7,20 59,88 53,37 51,63 54,96 3,55 70,47 66,16 78,26 71,63 5,00
10 97,56 121,28 122,09 113,64 11,38 113,84 96,86 87,33 99,34 10,96 99,65 84,30 92,33 92,09 6,27
2 105,12 103,37 101,63 103,37 1,42 107,56 102,44 92,21 100,74 6,38 99,30 80,70 104,77 94,92 10,30
Conc.
100 21,74 26,16 27,09 25,00 2,33 42,79 42,33 35,93 40,35 3,13 72,91 90,12 90,35 84,46 8,17
30 76,86 75,58 67,44 73,29 4,17 72,09 72,79 70,47 71,78 0,97 74,65 80,47 88,14 81,09 5,52
10 99,65 92,67 80,70 91,01 7,83 80,93 83,49 74,42 79,61 3,82 63,72 68,14 80,00 70,62 6,87
2 96,05 98,72 89,88 94,88 3,70 90,93 88,37 86,05 88,45 1,99 69,53 74,53 80,81 74,96 4,61
Conc.
100 50,81 44,88 49,88 48,53 2,60 70,00 66,28 67,67 67,98 1,53 84,65 87,09 108,26 93,33 10,60
30 95,00 91,16 78,02 88,06 7,27 82,67 76,05 72,09 76,94 4,37 74,42 94,42 91,63 86,82 8,84
10 97,21 111,74 90,81 99,92 8,76 90,93 84,42 83,60 86,32 3,28 76,40 93,84 80,93 83,72 7,39
2 90,23 90,70 76,40 85,78 6,64 98,60 91,63 95,23 95,16 2,85 94,65 110,35 104,88 103,29 6,51
Conc.
100 91,16 90,81 82,33 88,10 4,09 74,65 75,12 89,77 79,84 7,02 76,63 80,00 81,86 79,50 2,17
30 95,70 95,47 98,49 96,55 1,37 99,42 99,65 100,12 99,73 0,29 86,51 91,86 99,19 92,52 5,20
10 69,53 74,07 79,30 74,30 3,99 79,53 74,42 86,16 80,04 4,81 71,98 78,84 71,86 74,22 3,26
2 79,88 72,44 89,07 80,47 6,80 69,65 74,30 73,95 72,64 2,12 59,30 67,44 63,95 63,57 3,33
Conc.
100 85,70 31,63 35,35 50,89 24,66 6,98 6,51 5,47 6,32 0,63 59,30 66,51 60,12 61,98 3,22
30 100,00 100,00 90,35 96,78 4,55 73,84 74,65 85,35 77,95 5,25 64,77 60,12 59,77 61,55 2,28
10 113,02 111,28 97,33 107,21 7,03 93,84 81,16 101,86 92,29 8,52 69,53 80,23 74,30 74,69 4,38
2 108,49 113,95 104,65 109,03 3,82 97,21 87,91 111,28 98,80 9,61 83,26 75,93 83,60 80,93 3,54
Conc.
20 6,86 6,51 7,09 6,82 0,24 88,37 94,77 81,63 88,26 5,36 154,07 148,26 156,16 152,83 3,35
5 26,16 28,95 28,02 27,71 1,16 110,81 99,88 86,86 99,19 9,79 161,51 161,63 135,47 152,87 12,31
2 84,88 80,12 90,23 85,08 4,13 100,47 121,74 111,86 111,36 8,69 175,12 170,58 177,21 174,30 2,77
0,5 87,56 84,07 85,23 85,62 1,45 105,35 98,84 103,26 102,48 2,71 147,56 183,95 140,93 157,48 18,91
